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ABSTRACT
Trypanosoma cruzi is the causative agent of the life-threatening Chagas disease, in which
increased platelet aggregation related to myocarditis is observed. Platelet-activating factor (PAF) is a
potent intercellular lipid mediator and second messenger that exerts its activity through a PAF-specific
receptor (PAFR). Previous data from our group suggested that T. cruzi synthesizes a phospholipid with
PAF-like activity. The structure of T. cruzi PAF-like molecule, however, remains elusive. Here, we
have purified and structurally characterized the putative T. cruzi PAF-like molecule by electrospray
ionization-tandem mass spectrometry (ESI-MS/MS). Our ESI-MS/MS data demonstrated that the T.
cruzi PAF-like molecule is actually a lysophosphatidylcholine (LPC), namely sn-1 C18:1(delta 9)-LPC.
Similar to PAF, the platelet-aggregating activity of C18:1-LPC was abrogated by the PAFR antagonist,
WEB 2086. Other major LPC species, i.e., C16:0-, C18:0-, and C18:2-LPC, were also characterized in
all T. cruzi stages. These LPC species, however, failed to induce platelet aggregation. Quantification
of T. cruzi LPC species by ESI-MS revealed that intracellular amastigote and trypomastigote forms
have much higher levels of C18:1-LPC than epimastigote and metacyclic trypomastigote forms. C18:1LPC was also found to be secreted by the parasite in extracellular vesicles (EV) and an EV-free
fraction. A three-dimensional model of PAFR was constructed and a molecular docking study was
performed to predict the interactions between the PAFR model and PAF, and each LPC species.
Molecular docking data suggested that, contrary to other LPC species analyzed, C18:1-LPC is predicted
to interact with the PAFR model in a fashion similar to PAF. Taken together, our data indicate that T.
cruzi synthesizes a bioactive C18:1-LPC, which aggregates platelets via PAFR. We propose that C18:1LPC might be an important lipid mediator in the progression of Chagas disease and its biosynthesis
could eventually be exploited as a potential target for new therapeutic interventions.
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Glycosylphosphatidylinositol (GPI)-anchoring is a protein post-translational modification
ubiquitously found in eukaryotes. There is a growing body of evidence showing that protein-free GPIs
(or glycoinositolphospholipids, GIPLs) and GPI-anchored proteins (GPI-APs) are involved in hostprotozoan interaction processes, such as host-cell adhesion and invasion, and pathogenesis. Here, we
used a highly sensitive and unbiased approach that employs liquid chromatography-tandem mass
spectrometry (LC-MSn) for the analysis of the GPIome (GPIomics) of the mammal-dwelling
trypomastigote and amastigote stages of Trypanosoma cruzi, the causative agent of Chagas disease.
This approach allows for the structural characterization of both the lipid and the glycan moieties of
GPI-APs and GIPLs. We have identified over 140 GIPL and GPI-AP species from these two parasite
forms, most of which had not been described in the literature. In contrast to epimastigote-derived GIPLs
(eGIPLs), trypomastigote-derived and amastigote-derived GIPLs (tGIPLs and aGIPLs, respectively)
tend to have longer and structurally more diverse glycan moieties. Similar results were observed for
trypomastigote-derived and amastigote-derived GPI-APs (tGPI-APs and aGPI-APs, respectively),
although tGPI-APs and aGPI-APs tended to be structurally less diverse than their GIPL counterparts.
The lipid moieties of tGIPLs are composed mainly of O-alkyl-2-O-acyl-glycerolipids (AAGs), typically
with longer fatty acid chains than those of eGIPLs. Conversely, amastigotes tend to have an
approximately equal number of GIPLs containing AAG or ceramide moieties. Interestingly, the
majority of the lipid moieties of GPI-APs derived from both mammal-dwelling stages of T. cruzi
contain C18:1- or C18:2- fatty acid substituents. The proteomic analysis of fractions enriched in GPIAPs from the three life-stages of this parasite showed much greater protein diversity in the mammaldwelling stages than in epimastigotes. The observations made in this study will, hopefully, help us
further understand possible structure-function correlations of GPIs and their role during chronic
infection.
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1. CHAPTER 1: INTRODUCTION
1.1. Chagas Disease:
Chagas disease (Cd) is one of the major parasitic diseases in the Americas, affecting 8-10
million people worldwide. Cd has a broad spectrum of clinical outcomes, ranging from a
complete lack of symptoms to severe disease and, in many cases, death (1-3). The clinical course
of the disease includes an acute phase, an indeterminate phase, and a chronic phase. The acute
phase is characterized by very high parasitemia and often flu-like symptoms. The indeterminate
stage is characterized by a lack of clear manifestations of infection, with patients remaining
asymptomatic despite parasite persistence in blood and other tissues. About 20-30% of
chronically infected individuals develop cardiovascular disease, which leads to congestive
cardiac failure and sudden cardiac death, or develop gastrointestinal (GI) complications, like
megacolon or megaesophagus. Some patients may also show both cardiac and GI alterations (18). The other 70-80% of these individuals will either remain asymptomatic or develop
megaesophagous and/or megacolon syndromes. Both acutely-infected and chronically-infected
individuals also commonly exhibit an increase in platelet aggregation, focal ischemia, and
myonecrosis (9,10). The damages caused to these individuals during the chronic phase of this
disease are irreversible and, in many cases, lead to a lack of productivity (due to patient
morbidity) and to premature deaths (usually due to heart disease) (3,11).
In 2006, over 12,500 people died from Cd-related complications, mostly from sudden
cardiac arrest (1,2,8). Due to a marked increase in population migration from endemic countries,
Cd is becoming a considerable burden to Europe, Australia, Japan, and the USA (4-6). It is
estimated that 300,000 individuals infected with T. cruzi currently live in the USA, with 30,000-
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45,000 of them having developed cardiomyopathy and 315 having already disseminated the
disease congenitally (4,5,8).
The etiologic agent of Cd is the protozoan parasite Trypanosoma cruzi, which exhibits a
complex life-cycle with four distinct developmental stages. These parasites are naturally
transmitted by vector insects of the subfamily Triatominae (popularly known as kissing bugs),
which feed on mammalian blood. Whenever these insects feed on contaminated blood, they
ingest non-proliferative, infective bloodstream trypomastigotes, which convert into replicative,
noninfective epimastigotes in the vector’s midgut. After the blood meal is digested by the vector,
the epimastigotes undergo nutritional stress and migrate to the insect’s hindgut and transform
into non-replicative, infective metacyclic trypomastigote forms. The vector tends to defecate
either during or shortly after bloodfeeding, depositing concentrated infective metacyclic forms
near the bite wound. These parasites then gain access to the host through injured skin or exposed
oral or ocular mucosa, and then proceed to infect any nucleated cell in the body, usually
persisting indefinitely in tissues such as the heart and adipose tissue in the form of proliferative
intracellular amastigotes. The intracellular amastigotes will multiply in the host-cell cytoplasm,
eventually converting into bloodstream trypomastigote forms, which burst out of the host-cells to
either infect new surrounding cells or reach the bloodstream to infect other cells in various
tissues in the body. Eventually, the cycle is closed when another kissing bug consumes infected
blood. T. cruzi can also be transmitted orally, congenitally, via blood transfusion, or organ
transplantation (Fig.1) (1,2,9,12).

2

Figure 1.1: The life cycle of T. cruzi. (1) Metacyclic trypomastigotes (Metas) are released with vector droppings
shortly after a bloodmeal, where they gain access to the host via injured skin or exposed mucosa. (2) Metas quickly
infect host cells at the parasite entry site. (3) The parasites then transform into the replicative intracellular
amastigotes (ICAs) form. (4) ICAs divide by binary fission in the host-cell cytoplasm and convert into
trypomastigote (TCT) foms. (5-6) TCTs burst out of the host cell and into the bloodstream, where they may either
infect new host cells or be ingested by the insect vector during blood-feeding. (7-8) Once in the vector digestive tube
TCTs convert into the replicative epimastigote (Epi) forms, which multiply in the insect’s midgut. (9) As the
bloodmeal is digested, Epis will migrate to the vector’s hindgut, where they will transform into Metas, continuing
the cycle.
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Thus far, there are only two drugs (i.e., Nifurtimox and Benznidazole) available for Cd
treatment. Both drugs cause moderate to severe side effects (4,7), and neither of them being fully
efficacious for patients with chronic Cd (7). Moreover, no vaccines for the prevention and/or
treatment of Cd are currently available (1,2). Consequently, there is a great necessity for the
development of novel, more efficient therapies for Cd. The main objective of this project is to
identify and validate potential new molecular targets against T. cruzi. To this end, the two
molecular parasite targets we will focus in this disseration are (1) phospholipids, and (2)
glycosylphosphatidylinositol (GPI)-anchored glycocolipids and glycoproteins. The rationale
for this will be explained in detail in Chapters 2 and 3 of this dissertation.
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1.2 Specific aims
Specific aim 1: We aim to better understand the mechanisms behind the increase in platelet
aggregation during the acute and chronic stages of Cd.
Platelet-activating factor (PAF) is a potent intercellular lipid mediator and second
messenger that exerts its activity through a PAF-specific receptor (PAFR). Previous data from
our group suggested that T. cruzi synthesizes a phospholipid with PAF-like activity. The
structure of T. cruzi PAF-like molecule, however, remains elusive. Our hypothesis is that T.
cruzi either synthesizes a bona fide PAF, or a PAF-like molecule, which hadn’t been described
because of technical limitations involved in the purification and analysis of this type of molecule.
Our aim is to purify and characterize the molecule(s) responsible for the PAF-like activity of T.
cruzi lipid extracts. This aim will be explored in chapter 2 of this dissertation.

Specific aim 2: To carry out the detailed expression GPIomic analysis of the infective
mammalian-cell-derived trypomastigote and amastigote forms of T. cruzi.
Our laboratory has developed a high-throughput approach for the global analysis of a
class of glycolipids known as GPIs, which cover the surface of T. cruzi and are required for hostcell infection and modulation of the host imune response against the parasite. This approach (i.e.,
GPIomics) has only been employed so far for the global analysis of GPIs (GPIome) of the
noninfective insect-dwelling (epimastigote) stage of this parasite. Therefore, we plan to apply the
same strategy for the analysis of the GPIome of the mammal-dwelling (trypomastigote and
amastigote) parasite stages, which are responsible for causing chronic Cd in humans.
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Our hypothesis is that this method will help us identify new GPI structures and novel
GPI biosynthetic pathways that can be exploited for the development of new therapeutic
interventions for Cd. This aim will be explored in chapter 3 of this dissertation

The background for each specific aim will be provided in greater detail on the
chapter in which that aim is explored.
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2. CHAPTER 2: STRUCUTRAL AND FUNCTIONAL ANALYSIS OF A
PLATELET-ACTIVATING LYSOPHOSPHATIDYLCHOLINE OF
TRYPANOSOMA CRUZI

Notice: A significant portion of this chapter was originally published under the same title
on the journal "PLoS Neglected Tropical Diseases", 2014 Aug 7;8(8):e3077. doi:
10.1371/journal.pntd.0003077. eCollection 2014. Permission to republish the same content
in this chapter was granted by the editors (For more details, please see pages 139-140 of
this dissertation).

The original authors of the manuscript are: Felipe Gazos-Lopes, Mauricio M. Oliveira,
Lucas V. B. Hoelz, Danielle P. Vieira, Alexandre F. Marques, Ernesto S. Nakayasu, Marta
T. Gomes, Nasim G. Salloum, Pedro G. Pascutti, Thaıs Souto-Padron, Robson Q. Monteiro,
Angela H. Lopes, Igor C. Almeida.

2.1 Introduction
2.1.1 Lipids: Structure and Function
Lipids comprise of a diverse group of macromolecules, playing several important
biological roles, including the formation of the plasma membrane and of subcellular
compartments, energy storage, cell signaling, and protein trafficking (13-19). For decades, lipids
have been loosely defined as being hydrophobic metabolites that are soluble in solvents, but
insoluble in water. This broad definition encompasses several classes of molecules, such as
sterols, fatty acids, glycerophospholipids, sphingolipids, isoprenoids, and terpenes, among many
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others. Because of the tremendous functional and structural diversity of these molecules, it is not
surprising that several different lipid classification schemes have been proposed over the years.
In order to avoid ambiguity in the field of lipid biology and other related fields, the International
Lipid Classification and Nomenclature Committee (ILCNC) established a revised comprehensive
classification and nomenclature system for lipids using well-defined chemical principles. This
system was formulated as an expansion of the guidelines established by the International Union
of Pure and Applied Chemistry (IUPAC) (20,21). Under this new classification, lipids are
defined as “hydrophobic or amphipathic small molecules that may originate entirely or in part by
carbanion-based condensations of thioesters and/or by carbocation-based condensation of
isoprene units” (20). The new classification system acknowleges 8 lipid categories, namely
“Fatty Acyls” (FA), “Glycerolipids” (GL), “Glycerophospholipids” (GP), “Sphingolipids” (SP),
“Sterol Lipids” (ST), “Prenol Lipids” (PR), “Saccharolipids” (SL), and “Polyketides” (PK) (Fig.
2) (20). We will briefly describe the first six categories on this list, but will not go into detail on
the structure and function of SLs and PKs, because to date they have neither been described in
mammals or in any trypanosomatid model.

FAs are composed of a saturated or an unsaturated hydrocarbon chain and a terminal
carboxyl group. The length of most FAs range from 14 to 26 carbon atoms, and the number of
unsaturations found in these molecules usually range from 0 to 6. Derivatives of this basic
structure are considered as subclasses within this group. FAs are building blocks to several other
lipid categories, such as GLs, GPs, SPs, and cholesterol esters. FAs and their derivatives, such as
prostaglandins and leukotrienes, have been described to have important biological activities,
such as in inflammation and cell signaling events (22-25).
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PRs are synthesized from five-carbon isoprene units (26). These lipids play very diverse
biological roles, being precursors to several molecules, such as vitamins A, E and K, and sterols,
quinones, and hydroquinones (27-30). Also, PRs and phosphorylated PRs, such as dolichol
phosphate, play key roles in the biosynthesis of several classes of glycolipids and glycans, such
as glycosylphosphatidylinositols (GPIs) and N- and O-glycans, and in the synthesis of the cell
walls of several organisms (31-33).

STs consist of cholesterol and its derivatives, as well as other related molecules (usually
refered to as “steroids”). They share a four ring core structure, and are important membrane
components, helping regulate membrane fluidity (34). They also participate in cell signaling
events, play several roles in inflammation, act as hormones, and even play a role in digestion in
vertebrates (34-36) .

SPs are a complex family of compounds derived from a sphingoid base, which is a
backbone synthesized from the condensation of a serine and a fatty acid-CoA. Of relevance to
this dissertation are ceramides (Cers) and inositolphosphoceramides (IPCs), which are N-acylderivatives of sphingosine. Typically, the amide-linked fatty acids in Cers are saturated or
monounsaturated long carbon chains varying in length from 14 to 26 carbon atoms. Their
sphingoid backbones usually have 16 to 18 carbons atoms and are either saturated or
monounsaturated. IPCs are formed through the addition of a phosphorylinositol headgroup to
ceramides via a phosphodiester linkage. These molecules play a plethora of structural and
signaling roles, which are beyond the scope of this dissertation (20,37).

GLs mainly include monoacylglycerides (MAGs), diacylglycerides (DAGs), and
triacylglycerides (TAGs). These lipids consist of a glycerol backbone to which one or more FAs
9

may be esterified to its hydroxyl groups (38). Some organisms add fatty alcohols, instead of fatty
acids, to the glycerol backbone. TAGs are most commonly known for their role in the storage of
cellular energy and from being the main constituents of anima-derived fat, but it has also been
shown that several diseases are associated to changes in their metabolism (39,40).

GPs also have a glycerol backbone, but are distinguished from other GLs because of the
presence of a functional polar “head group” esterified to either the sn-3 position (Eubacteria and
Eukarya) or sn-1 position (Archea) via a phosphodiester bond. The other two positions may
either have a hydroxyl group or may be modified with either a fatty acid or with a fatty alcohol.
Based on the composition of the head group, GPS are usually divided into glycerophosphatidic
acids

(PA),

glycerophosphocholines

(PC),

glycerophosphoethanolamines

(PE),

glycerophosphoserines (PS), glycerophosphoglycerols (PG), and glycerophosphoinositols (PI).
Whenever only either the sn-1 or the sn-2 positions are esterified, the lipid is reffered to as a
“lyso-GP”. As an example, a GP with only one fatty acid and a phospocholine head group is
reffered to as a “lyso-PC”. GPs are the main components of cell membranes, and participate in
several biological processes, such as cell signaling and molecular trafficking (41-43).
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Figure 2: Representative lipids from each of the 8 categories proposed by the new ILCNC system. Figure modified
from (20).
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2.1.2 - Bioactive lipids in T. cruzi and their role in Chagas disease
In general, lipid mediators (44,45) nd specifically, lysophosphatidylcholine (LPC) (46),
have been implicated in experimental models of Cd. LPC is present in the saliva of at least one
of the insect vectors of Cd, the hemipteran Rhodnius prolixus, where it acts as an anti-hemostatic
molecule and immunomodulator of T. cruzi infection in a mammalian model ((46), (47), (48)).
LPC (1-acyl-2-hydroxy-sn-glycero-3-phosphorylcholine) is a major plasma phospholipid of
oxidized low-density lipoproteins (Ox-LDL), albumin, and other carrier proteins, being a critical
factor in the inflammatory processes and the atherogenic activity of Ox-LDL ((49), (50), (51)).
LPC is an intracellular modulator that activates several second messengers, controlling important
biological activities, such as cellular proliferation and differentiation, transcription of adhesion
molecules and growth factors in endothelial cells, and transportation of fatty acids, choline, and
phosphatidylglycerol between tissues (49), (50), (51), (52), (53). The biological activities of LPC
are usually mediated by G protein-coupled receptors (GPCRs), such as G2A, GPR4, and the
receptors for prostacyclin (IP), thromboxane A2 (TXA2) (TP), and platelet-activating factor
(PAF) (PAFR) ((53), (54), (55), (56), (57), (58), (59), (60), (61), (62)). Specifically, LPC species
are capable of eliciting different cellular activities depending on the length and degree of
unsaturation of its sole acyl-chain ((59), (63), (64)). Trypanosomatid parasites (e.g., T.
brucei, Leishmania spp., and T. cruzi) are known to synthesize phosphatidylcholine (PC) and
LPC. Over 50% of the total lipids shed to the culture medium by T. cruzi were identified as PC
and LPC (65). These molecules were also found in Leishmania ((66), (67)), African
trypanosomes ((68)), and in the malaria parasite, Plasmodium falciparum ((69)). To the best of
our knowledge, however, the chemical structures of LPC species synthesized by T. cruzi have
not been defined to date.
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Platelet-activating factor (1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine; PAF) is
structurally very similar to LPC ((70)). PAF exhibits potent biological activity and is synthesized
by a wide variety of cells, including neutrophils, platelets, macrophages, and lymphocytes ((71)).
PAF induces numerous physiological and pathophysiological effects, such as cellular
differentiation, inflammation, and allergy, through the activation of specific GPCRs with seven
transmembrane helices ((54), (72)). We have previously shown that T. cruzi synthesizes a lipid
with platelet-aggregating properties similar to PAF ((73)). Preliminary structural analysis by
chemical and enzymatic treatment indicated that the T. cruzi PAF-like lipid, metabolically
labeled with 14C-acetate, was labile to mild-alkaline or hydrofluoric acid hydrolysis, suggesting a
molecule containing a glycerolipid moiety with at least one acyl chain and a phosphate
group ((73)). However, the detailed structure of the T. cruzi PAF-like lipid remains elusive.
Here, we describe the identification and bioactivity of the as-yet elusive T. cruzi PAF-like
molecule. We use a novel approach for the enrichment of this and other closely related
lysophospholipids, followed by tandem mass spectrometry (MSn) to provide ample structural
information. Moreover, we constructed a 3-D molecular model of PAFR and used molecular
docking to predict the interactions of the T. cruzi PAF-like molecule and other lysophospholipids
with this receptor.
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2.2 Materials and Methods
2.2.1 - Ethics statement Heading
Rabbit platelets used in this study were obtained following the guidelines of the
Committee for Evaluation of Animal Use for Research of the Federal University of Rio de
Janeiro (CAUAP-UFRJ) and the NIH Guide for the Care and Use of Laboratory Animals. The
vertebrate animal protocol was approved by CAUAP-UFRJ under registry number IBQM011.

2.2.2 Chemicals
Synthetic C16:0-, C18:0-, C18:1(Δ9)-, and C22:6-LPC, and C16:0-PAF were purchased
from Avanti Polar Lipids (Alabaster, AL). The competitive PAF antagonist WEB 2086 (4-[3-[4(2-chlorophenyl)-9-methyl-6h-thieno[3,2-f]

((74),(10),(75))

triazolo[4,3-a]diazepin-2-yl]-1-

oxopropyl]morpholine) was kindly provided by Dr. H. Heurer from Boehringer Ingelheim
(Ingelheim, Germany). Otherwise indicated, all other reagents and solvents used here were of
analytical, HPLC, or mass spectrometric grade from Sigma-Aldrich (St. Louis, MO).

2.2.3 Trypanosoma cruzi culture
All T. cruzi life cycle stages or forms were obtained from the Y strain ((76)).
Epimastigote forms (Epis) were maintained by weekly transfers using liver infusion tryptose
(LIT) medium ((77)), supplemented with 0.002% hemin and 10% heat-inactivated fetal calf
serum (FCS; Hyclone, heat-inactivated at 56°C for 30 min) at 28°C. Metacyclic trypomastigote
forms (Metas) were obtained by spontaneous axenic differentiation of Epis at 28°C, followed by
their purification using ion-exchange chromatography ((78), (79)). Mammalian tissue culturederived trypomastigotes (TCTs) were obtained from the supernatants of 5 to 6 days old T. cruzi14

infected LLC-MK2 cells (American Type Culture Collection, Rockville, MD), maintained in
RPMI-1640 medium supplemented with 2% FCS at 37°C in a 5% humidified
CO2 atmosphere ((80)). Intracellular amastigotes (ICAs) were obtained as described ((81)).
Briefly, infected monolayers of LLC-MK2 cells were gently detached by scraping (BD Falcon
cell scraper, BD Biosciences) and resuspended in PBS supplemented with 10% FCS.
Mammalian cells were disrupted by passage through a 27-gauge needle (BD, Becton and
Dickinson & Co.). ICA forms were separated from the cell debris by centrifugation (800× g for 5
min at 4°C). The supernatant was then harvested and passed through a DE-52 column and
parasites were incubated for 2 h at 37°C in a humidified 5% CO2 atmosphere, after which the
parasites were again passed through a DE-52 column, from which they were harvested and
stored. For the viability testing of all parasite forms, cells were resuspended in a Trypan Blue
solution and counted in a Neubauer chamber ((82)). In this study, all experiments were
performed using parasites that were harvested by centrifugation and washed three times with
PBS before use, unless otherwise specified. All parasite forms were counted and then frozen in
liquid nitrogen prior to use.

2.2.4 Lipid extraction
Frozen pellets derived from Epis, Metas, ICAs, and TCTs (2×109 cells each), were
suspended in 1.6-ml ice-cold HPLC-grade water and transferred to 13×100-mm Pyrex culture
tubes with polytetrafluoroethylene (PTFE)-lined screw caps. HPLC-grade chloroform and
methanol were added to each vial, giving a final ratio of chloroform/methanol/water (C/M/W) of
1:2:0.8 (v/v/v). The samples were mixed vigorously using a vortex for 2 min and then
centrifuged for 15 min at 1,800× g at room temperature. After centrifugation, the supernatants
were transferred to PTFE-lined Pyrex glass test tubes and the pellets were dried under a constant
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flow of N2 stream. The dry pellets were then extracted three times with C/M (2:1, v/v) and twice
with C/M/W (1:2:0.8, v/v/v). After extraction, the supernatants were pooled together and dried
before being subjected to Folch's partition ((83,84)). To this end, samples were first dissolved in
C/M/W (4:2:1.5, v/v/v) and then mixed vigorously for 5 min using a vortex and finally
centrifuged for 15 min at 1,800× g at room temperature. After centrifugation, the lower (organic)
and upper (aqueous) phases were separated in PTFE-lined Pyrex glass test tubes. The Folch
lower phase was then washed two times with a freshly prepared upper phase, dried under
N2 steam, and stored at −70°C until use.

2.2.5 Solid-phase extraction (SPE) of phospholipids
Phospholipids derived from the lower phase of the Folch's partition, as described above,
were purified from other classes of lipids using a three-step SPE protocol ((85)). Briefly, 100 mg
silica gel (Merck, grade 7754, high purity, 70–230 mesh, 60 Å) were packed into borosilicate
glass Pasteur pipettes (5 ¾″, Fisher Scientific) using Pyrex glass fiber wool (8-µm pore size,
Sigma-Aldrich) as a sieve. The column was sequentially conditioned with 4 ml each methanol,
acetone, and chloroform. Dried Folch lower phase samples from all T. cruzi life stages were
redisolved in 3 ml chloroform and a third of each sample was added to the column. Lipids were
sequentially eluted with 4 ml chloroform (neutral lipids), acetone (glycolipids), and methanol
(phospholipids and free fatty acids). Each fraction was collected into a 7-ml amber glass vial
with PTFE-lined screw top (SUPELCO, Sigma-Aldrich). All samples were immediately dried
under a constant flow of N2 stream and stored at −70°C until use.
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2.2.6 T. cruzi PAF-like phospholipid enrichment
With the purpose of enriching the putative PAF-like molecule from a complex T. cruzi
phospholipid mixture, a novel method was developed using perfusion chromatography ((86)).
Briefly,

fifty

microliters

of

a

suspension

of

40

mg/ml

POROS

R1

50

(poly[styrene/divinylbenzene], with similar binding strength as C4 supports) beads (Applied
Biosystems, 50-µm diameter) in HPLC-grade n-propanol (Honeywell, Burdick & Jackson,
Radnor, PA) were packed into a 200-µl sterile micropipette tip (Axygen, Corning Life Sciences,
Union City, CA). Pyrex glass fiber wool (8-µm pore size, Sigma-Aldrich) was used as sieve. The
POROS R1 mini-column was washed twice with 100 µl HPLC-grade methanol and then
conditioned with an n-propanol/water gradient (from 50% to 0%, in 5% increments). Each step
of the gradient was performed with 100 µl solvent, with the exception of the last step (0% npropanol), which was performed twice with 100 µl HPLC-grade water. Then, either the mixture
of lipid standards (100 pmol C16:0-lyso-PC (C16:0-LPC), C16:0-lyso-PAF (C16:0-LPAF),
C16:0-PAF, and C18:0/C18:1-diacyl-PC) or T. cruzi phospholipids derived from the SPE
procedure were suspended in HPLC-grade water, sonicated for 10 min in a bath sonicator, and
added to the column. Both the standards and the phospholipid extracts were eluted using a 0%–
50% n-propanol gradient in 5% n-propanol increments. Each fraction was stored in Axygen 2-ml
microcentrifuge tube at −70°C until further use.

2.2.7 Structural characterization of LPC species by tandem electrospray
ionization-linear ion trap-mass spectrometry (ESI-LIT-MS)
All fractions derived from the POROS R1 mini-column purification, as well as the
fractions obtained prior to this last procedure (namely, the lower Folch and methanol phase),
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were dissolved in MS-grade methanol containing 5 mM LiOH, as indicated. Samples were
directly injected (at 300 nl/min) by chip-based infusion using a TriVersa NanoMate
nanoelectrospray source (Advion, Ithaca, NY), into an LTQXL ESI-linear ion trap-MS (ESILIT-MS) (Thermo Fisher Scientific), in positive-ion mode. The source voltage was set at 0.01
kV and current at 0.03 µA; capillary voltage and temperature were 36 V and 150°C, respectively;
and tube lens voltage was set at 145 V. Select ions were subjected to sequential tandem
fragmentation (MSn) by collision-induced dissociation (CID). Full-scan (MS) spectra were
collected at the 400–1000 m/z range. Tandem mass fragmentation was carried out using
normalized collision energies of 35, 40, and 45 for MS2, MS3, and MS4, respectively. The
resulting spectra were compared to the aforementioned phospholipid standards, as well as to
previously described results.
The location of the acyl chain on T. cruzi LPC species was determined by MS2 and
M3 analysis, essentially as described by Hsu et al. ((87)). Briefly, sn-1 and sn-2 C18:1-LPC
regioisomer standards were generated by treatment of 18:1(Δ9-cis)-PC (1,2-dioleoyl-sn-glycero3-phosphocholine, catalog # 850375, Avanti Polar Lipids) with either PLA2 (from porcine
pancreas, catalog # P6534, Sigma-Aldrich) or PLA1 (from Thermomyces lanuginosus, catalog #
L3295, Sigma-Aldrich). For PLA1 treatment, one mg of diacyl-PC standards were dried under
N2 stream, redisolved in 200 µL of reaction buffer (50 mM Tris-HCl, 2 mM CaCl2, 140 mM
NaCl, pH 8.0) and sonicated for 30 min. Afterwards, the samples were incubated at 37°C for 2 h
in the presence of 12 units PLA1. The reaction was interrupted by the addition of 1.5 mL
chloroform, followed by vortexing for 1 min. The resulting LPC species present in the organic
phase of the mixtures were then purified by SPE, following the protocol described above.
Finally, LPCs were recovered in the methanolic phase of the SPE column. PLA2 treatment was
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performed following the same procedure steps used for PLA1 treatment but using a different
reaction buffer (100 mM Tris-HCl, 5 mM CaCl2, 100 mM NaCl, pH 8.0) and 5 units
PLA2 ((88)). The purified lipids (methanolic phase of the SPE) were analyzed by ESI-LIT-MS
in 100% methanol containing 5 mM LiOH or 5 mM NaCl. The MS analyses were performed as
described above. The assignment of the fatty acid position on the LPC (sn-1 or sn-2) was
performed by comparing the fragmentation pattern of standard sn-1 and sn-2 C18:1-LPCs with T.
cruzi-derived 18:1-LPC samples.
The position of the double bond on fatty acid substituents was determined by MS4,
essentially as described by Hsu et al. ((89)). Briefly, sn-1 C18:1(Δ6-cis)-LPC and sn-1
C18:1(Δ9-cis)-LPC standards were generated by treatment of both 18:1(Δ6-cis)-PC (1,2dipetroselenoyl-sn-glycero-3-phosphocholine, catalog # 850374, Avanti Polar Lipids) and
18:1(Δ9-cis)-PC (1,2-dioleoyl-sn-glycero-3-phosphocholine, catalog # 850375, Avanti Polar
Lipids) with PLA2 (from porcine pancreas, catalog # P6534, Sigma-Aldrich), as described
above. LPC species were recovered from incubation mixtures and analyzed by ESI-LIT-MS in
100% methanol containing 5 mM LiOH, as described above.

2.2.8 Quantification of T. cruzi LPC species
Commercial C10:0-LPC (1-decanoyl-2-hydroxy-sn-glycero-3-phosphocholine, catalog #
855375, Avanti Polar Lipids) was used as an internal standard to quantify the most abundant
LPC species found in T. cruzi samples. Briefly, 18 nmoles of standard C10:0-LPC were added to
parasite pellets (7×108 cells) shortly before lipid extraction. Lipid extraction was conducted on
freshly prepared parasite pellets following the protocol described above. Then, the Folch lowerphase fractions were analyzed by ESI-MS (at the 400–1000 m/z range) under the identical MS
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conditions used for the characterization of T. cruzi LPCs. The amount of each LPC species was
calculated

using

the

formula:

[T.

cruzi LPC

peak

intensity/C10:0-LPC

peak

intensity]×[concentration of C10:0-LPC (18 pmol/µl)/MRRF], where, MRRF stands for the
molar relative response factor of each LPC species to the C10:0-LPC standard. The MRRF was
calculated by dividing the intensity of the peak corresponding to a standard LPC (C16:0-LPC,
C18:0-LPC, or C18:1-LPC) by the intensity of the peak corresponding to C10:0-LPC (m/z
418.5), when all molecules were in equimolar concentrations.
T. cruzi LPC species were also quantified in extracellular vesicles (EV) and EV-free
supernatant or conditioned medium (VF) of Epis (eV2, eV16, and eVF) and Metas (mV2, mV16,
and mVF), obtained from Epi and Meta pellets (9×109 parasites each), as previously described
((90)). C10:0-LPC (m/z 418) (18 nmoles per sample) was used as an internal standard. LPC
species were extracted from Epi- and Meta-derived EVs, and respective total parasite pellets
(ePellet and mPellet) as described above. The Folch lower phase fractions were analyzed by ESILIT-MS as above.

2.2.9 Platelet aggregation assay
C16:0-PAF and various synthetic (C16:0-, C18:0-, C18:1-, and C22:6-LPC) or purified
(C18:2-LPC) LPC species were tested in a platelet aggregation assay ((91)). Rabbit blood
platelets were prepared from blood collected with 5 mM EDTA as anticoagulant, isolated by
centrifugation, washed and resuspended in a modified Tyrode's buffer, pH 7.4, containing 2 mM
CaCl2, at a final concentration of 3–4×105 cells/µl in Tyrode's buffer. Platelet aggregation
experiments were performed with a Chronolog Aggregometer (Havertown, PA, USA), with
monitoring time of 5 min. Rabbit platelets used in this investigation were obtained following the
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guidelines for animal experimentation of the USA National Institutes of Health and the
experimental protocol received official approval of the Institutional Animal Care and Use
Committee, Universidade Federal do Rio de Janeiro.

2.2.10 Comparative modeling
The amino acid sequence of the human PAF receptor (PAFR, UniProtKB ID: P25105)
was obtained from ExPASy server ((92)). The region between Asp10-Ser310, part of PAFR
sequence that includes all seven-transmembrane domains, was submitted to I-TASSER server,
which combines threading and ab initio algorithms ((93), (94)). The I-TASSER server, ranked as
the best server in recent CASP7 and CASP8 experiments, builds protein models based on
multiple-threading alignments by LOMETS program and iterative TASSER program simulations
((95), (94)). In addition, MODELLER v9.10 program ((96), (97)) (http://salilab.org/modeller/)
was used to add a disulfide bridge between Cys90-Cys173 and, subsequently, to refine the best ITASSER model. Thus, the final model was validated using three programs: PROCHECK ((98))
and ERRAT ((99)) both at SAVES server (http://nihserver.mbi.ucla.edu/SAVES_3/) and
PROQM

((100))

(available

as

a

server

at http://www.bioinfo.ifm.liu.se/services/P

roQM/index.php?about=proqm). PROCHECK analyzes the stereochemical quality and ERRAT
evaluates the non-bonded atomic interactions in the model structure, while PROQM uses a
specific-scoring function for membrane protein, including GPCR, to assess local and global
structural quality of the model.
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2.2.11 Molecular docking
The ligand structures (C16:0-PAF, C16:0-LPC, C18:0-LPC, C18:1-LPC, and C18:2LPC) were built in the Spartan'10 software (Wavefunction, Inc., Irvine, CA). The docking of the
ligands to the PAFR model binding site was performed using Molegro Virtual Docker (MVD)
program (CLC bio, Aarhus, Denmark), which uses a heuristic search algorithm that combines
differential evolution with a cavity prediction algorithm. The MolDock scoring function used is
based on a modified piecewise linear potential (PLP) with new hydrogen bonding and
electrostatic terms included. Full description of the algorithm and its reliability compared to
other common docking algorithm has been described ((101)). As no satisfactory cavities were
found by cavity prediction algorithm using MVD, His248 (a constituent residue of the binding
pocket) was set as center of searching space. The search algorithm MolDock optimizer was used
with a minimum of 50 runs and the parameter settings were: population size = 200; maximum
iteration = 2000; scaling factor = 0.50; offspring scheme = scheme 1; termination scheme =
variance-based; crossover rate = 0.90. Due to the stochastic nature of algorithm search, ten
independent simulations per ligand were performed to predict the binding mode. Consequently,
the complexes with the lowest interaction energy were evaluated. The interactions between
PAFR and each ligand were analyzed using the ligand map algorithm, a standard algorithm in
MVD program. The usual threshold values for hydrogen bonds and steric interactions were used.
All figures of PAFR modeling and docking were edited using Visual Molecular Dynamics
(VMD) program (available for download at http://www.ks.uiuc.edu/Research/vmd/vmd-1.9.1/).
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2.3 Results
2.3.1 Enrichment of LPC and PAF from complex mixtures
Previous results from our group strongly indicated that T. cruzi synthesizes a
phospholipid with platelet-aggregating activity similar to PAF ((73)) Thus far, however, the
precise structure of this bioactive parasite-derived molecule remains unknown. Aiming at the
enrichment and characterization of the putative T. cruzi PAF-like phospholipid from a complex
phospholipid mixture, we developed a fractionation protocol, which included solvent extraction
and Folch's partition, followed by SPE and perfusion chromatography (Fig. 3). Lipid fractions
obtained after each step of purification were analyzed by ESI-LIT-MS in positive-ion mode.
Total-ion mapping (TIM) for the neutral loss of the trimethylamine group ( = 59 a.m.u.) was
performed to promptly localize phosphocholine-containing phospholipids of all life-cycle stages
of T. cruzi (data not shown). ESI-LIT-MS analysis of the Folch lower phase of the four parasite
forms (Epi, Meta, ICA, and TCT) showed major phospholipid species at the 700–900 m/z range,
except for the ICA form (Fig. 4A). Tandem MS (MSn) analysis of these lipid species revealed
that, as expected, they were mostly diacyl-PC and sphingomyelin (SM) species (data not shown,
to be published elsewhere). In contrast to other parasite forms, ICA is much richer in lipid
species at the 500–600 m/z range, particularly m/z 526, 528, 530, and 574 (Fig. 4A). Noteworthy,
lithiated singly-charged ion species ([M+Li]+) of synthetic LPAF, LPC, and PAF standards were
found at this range of the spectrum (Fig. S1, top spectrum). ESI-LIT-MS analysis of SPEderived fractions of all T. cruzi forms revealed a clear enrichment of phosphocholine-containing
lipids at the low m/z range (400–600), which would indicate an enrichment of potential LPC,
LPAF, or PAF molecules. Nevertheless, most samples still contained high amounts of diacylPCs and, possibly, SMs (data not shown). Therefore, a novel protocol using POROS R1 beads
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was designed to enrich the putative PAF-like molecule, which as we predicted could have a
structure similar to PAF, LPAF, or LPC. First, we tested the POROS R1 mini-column with a
complex mixture of phospholipid standards containing LPAF, LPC, PAF, and diacyl-PCs. We
were able to obtain highly enriched LPAF, LPC, and PAF species in the 20% and 25% npropanol fractions (Fig. S1). Identical conditions were applied for further fractionation of the
phospholipids present in the SPE methanolic fraction of all T. cruzi forms. The 25%-n-propanol
fractions from these parasite stages were then compared by positive-ion mode ESI-LIT-MS,
using the same concentration of cells (4×105/µl) and flow rate (300 nl/min) (Fig. 4B). The ion
species at the 700–900 m/z range, corresponding to diacyl-PCs and SMs, were noticeably much
less abundant in the 25%-n-propanol POROS R1 fraction (Fig. 4B) than in the Folch lower phase
and SPE methanolic fractions (Fig. 4A and data not shown), which is in agreement with the
observed phospholipid standard results (Fig. S1). In contrast, the ion species at the 400–
600 m/z range were prominently more abundant in the 25%-n-propanol POROS R1 fraction than
in lower Folch and SPE methanolic fractions (Fig. 4A, B and data not shown). In particular, the
ion species at m/z 526 and 528 were remarkably abundant in the infective TCT form and in the
noninfective ICA form. Tandem MS was then performed for the elucidation of the molecular
structures of all phosphocholine-containing lysophospholipids at the 400–600 m/z range.
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Figure 3: Schematic representation of the methodology used for the enrichment and analysis of the putative
T. cruzi PAF-like phospholipid. The total lipid content of the pellets from T. cruzi epimastigote (Epi), metacyclic
trypomastigote (Meta), tissue culture-derived trypomastigote (TCT), or intracellular amastigote (ICA) forms was
extracted with organic solvents followed by Foch’s partition. Folch lower-phase samples were fractionated by SPE
in a silica gel (60 A˚) column. The different lipid classes were eluted with chloroform (neutral lipids), acetone
(glycolipids), and methanol (phospholipids). The latter was further fractionated by perfusion chromatography using
POROS R1 50 mini-columns, eluted with a 0%–50% n-propanol gradient. All fractions were diluted in methanol
containing 5 mM LiOH and analyzed by MSn. The inset depicts the T. cruzi life cycle with the four stages used in
this study. Picture taken from Gazos-Lopes et al, 2015, PLoS neglected tropical diseases 8, e3077
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Figure 4: Full ESI-LIT-MS spectra of T. cruzi phospholipids.(A) MS1 spectra of lipids obtained in the Folch
lower phase prior to fractionation. Lipid samples from all T. cruzi stages were diluted in methanol containing 5 mM
LiOH and analyzed by direct infusion in an LTQXL ESI-LIT-MS (positive-ion mode, MS+). Note that the region of
spectrum corresponding to LPAF, LPC, and PAF species in Epi, Meta, and TCT has been magnified for better
visualization. (B) MS1 spectra of phospholipids obtained by SPE followed by POROS R1 fractionation. Lipids
eluted in 25% n-propanol were diluted in methanol containing 5 mM LiOH and analyzed as above. Since the same
initial total number of cells (5×108) was used for lipid fractionation from each parasite stage, all spectra were
normalized. Magnification of the MS range where PAF and LPC species would be found is indicated (insets). Epi,
epimastigote; Meta, metacyclic trypomastigote; ICA, intracellular amastigote; TCT, tissue culture-derived
trypomastigote.m/z, mass to charge ratio. Picture taken from Gazos-Lopes et al, 2015, PLoS neglected tropical
diseases 8, e3077.
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2.3.2

Structural

characterization

and

quantification

of T.

cruzi

lysophospholipid species by tandem MS

The fragmentation pattern of the synthetic C16:0-PAF standard (m/z 530) was compared
to those of synthetic C18:0- and C18:1-LPC standards (m/z 530 and 528, respectively), because
certain PAF and LPC species may be isobaric. The assignment of the lysophospholipid species
found in the 25%-n-propanol POROS R1 fraction of all T. cruzi forms was based on the
fragmentation pattern of these standards, as well as on previously reported results ((70), (87),
(89)). Tandem MS (MS2) analysis of singly-charged, lithiated C16:0-PAF, C18:0-LPC, and
C18:1-LPC ion species gave rise to fragment ions at m/z 471, 471, and 469, respectively,
corresponding to the neutral loss of 59 a.m.u. (= trimethylamine group). The fragmentation of
16:0-PAF standard, however, also gave rise to a fragment ion at m/z 341, consistent with the
neutral loss of the whole phosphocholine headgroup along with the lithium adduct (−189 a.m.u.).
This fragment could not be detected on either LPC standards (Fig. S2A). MS3Fragmentation of
the major ions obtained by MS2 of C16:0-PAF, C18:0-LPC, and C18:1-LPC (i.e., m/z 471, 471,
and 469), gave rise to the major non-lithiated ion fragments at m/z 341, 341, and 339,
respectively, corresponding to the loss of 130 a.m.u. ( = ethyl phosphate group+Li) (Fig. S2B).
In addition, we observed lithiated ion fragments at m/z 347, 347, and 345, corresponding to the
loss of 124 a.m.u. ( = ethyl phosphate group), for C16:0-PAF, C18:0-LPC, and C18:1-LPC,
respectively. Interestingly, C18:0-LPC and C18:1-LPC also gave rise to two fragment ions
(m/z 291 and 289, respectively) that could not be detected in the C16:0-PAF standard. These
fragment ions corresponded to the lithiated ([R1CO2H+Li]+) stearoyl (m/z 291) and oleyl chains
(m/z 289), after the loss of choline (N+(CH3)3(CH2)2OH) from the precursor ions m/z 427 and
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425, respectively (Fig. S2B) ((87)). Finally, we carried out MS4 analysis of the major fragment
ion species obtained by MS3 of C16:0-PAF, C18:0-LPC, and C18:1-LPC standards (m/z 341,
341, and 339, respectively) (Fig. 5). A complex fragmentation pattern that provided ample
structural information for all three standards was observed. In these spectra, it was possible to
identify fragment ions generated by the loss of the acetyl group at the sn-2 position of C16:0PAF (m/z 281 and 263), and a fragment ion corresponding to the protonated C16:0-alkyl chain
(R1+) (m/z 225). Moreover, a series of fragments resulting from the loss of methylene groups ( =
14 a.m.u.) from the PAF C16:0-alkyl chain could also be seen below m/z 225. Similar
information could be obtained from the C18:0-LPC and C18:1-LPC, where fragment ions
derived from the protonated stearoyl (m/z 285, 267, and 249) and oleyl (m/z 265 and 247) acyl
chains at the sn-1 position could be identified ((87)). In both cases, a series of fragments
corresponding to the loss of methylene units could also be seen below m/z 240 (Fig. 5). Based on
the fragmentation pattern of the standards in MS2, MS3, and MS4, we could assign the different
lysophospholipid species of T. cruzi enriched in the POROS R1 25%-n-propanol fraction. As
observed in Figs. 5,

and S2A,B, the parent ions at m/z 526, 528, and 530 corresponded to

C18:2-LPC, C18:1-LPC, and C18:0-LPC, respectively. The lithiated ([R1CO2H+Li]+), nonlithiated ([R1CO+]+, and dehydrated [R1CO+ - H2O]+) fragment ions of linoleyl (m/z 287, 263,
and 245), oleyl (m/z 289, 265, and 247), and stearoyl (m/z 291, 285, 267, and 249) chains,
respectively, corroborated our assignments of T. cruzi (Tc) m/z 526, 528, and 530 as C18:2-,
C18:1, and C18:0-LPC (Figs. 5, and S2A,B). No detectable traces of C16:0-PAF (isobaric to
C18:0 LPC) or any other PAF-like species could be found. The structure and the fragmentation
pattern of C16:0-PAF and the major T. cruzi LPC species are represented in Fig. 6.
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Figure 5: ESI-LIT-MS4 analysis of major T. cruzi ion species enriched by POROS R1 fractionation.
Phospholipid standards (C16:0-PAF, C18:0-LPC, and C18:1-LPC) or T. cruzi phospholipids from the POROS R1
25% n-propanol fractions were diluted in methanol containing 5 mM LiOH and then infused directly into the
LTQXL MS. Fragment ion species resulting from neutral loss of 59 m/z (trimethylamine) from the parent ion at
MS2 were selected for MS3 fragmentation (Suppl. Figs. 2A and 2B). Then, ion species resulting from neutral loss of
189 m/z (phosphocholine+Li) from parent ions observed at MS3 were selected for MS4 fragmentation. All spectra
shown were obtained from TCT preparation. Identical fragmentation patterns were observed from Epi, Meta, and
ICA samples. Picture taken from Gazos-Lopes et al, 2015, PLoS neglected tropical diseases 8, e3077.
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Figure 6: Proposed molecular structures of the three major LPC species of T. cruzi.
Fragment ions obtained from the MSn analysis of T. cruzi ion species at m/z 530, 528, and 526 are indicated. The
tandem fragmentation of C16:0-PAF standard is included as a reference. Picture taken from Gazos-Lopes et al,
2015, PLoS neglected tropical diseases 8, e3077.
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The MSn experiments carried out above, however, could not provide sufficient structural
information to determine the position of the fatty acid (sn-1 or sn-2) and the location of the
double bonds on three major LPCs of T. cruzi. To address this point, we first generated LPC
standards with fatty acids on either the sn-1 or sn-2 position by treating diacyl-PCs with
commercial PLA2 and PLA1, respectively. Following protocols by Hsu et al. ((87)), we were
able to determine that the acyl chain in the three major T. cruzi LPCs was localized at the sn-1
position. In Figs. S3A,B, the fragmentation spectra (MS2 and MS3) of sodiated and lithiated sn-1
C18:1-LPC, sn-2 C18:1-LPC, and T. cruzi C18:1-LPC (from ICA form) are shown. In agreement
with Hsu et al. ((87)), the relative abundance of the sodiated parent ion (m/z 544) to the fragment
ion (m/z 485), corresponding to the loss of trimethylamine (−59 a.m.u), could be used to
differentiate between the two possible regioisomers (Fig. S3A). Clearly, T. cruzi C18:1-LPC
showed a fragmentation pattern consistent with an acyl chain located at sn-1. This result was
corroborated by the fragmentation spectrum of the lithiated T. cruzi C18:1-LPC (Fig. S3B). In
this

case,

the

relative

abundance

of

the

fragment

ion

at m/z 425

[M

–

N+(CH3)3(CH2)2OH+Li+]+ to the ions at m/z 339 (M - 189) and m/z 345 (M - 183) was used to
corroborate the sn-1 position of the acyl chain on T. cruzi C18:1-LPC. We carried out identical
experiments with T. cruzi C18:0- and C18:2-LPC and found that both contained the acyl chain at
the sn-1 position (data not shown).
To address the location of the double bonds in T. cruzi C18:1- and C18:2-LPC, we
followed the protocols described by Hsu and Turk ((103)). By comparing the MS4 spectra of Δ9and Δ6-C18:1-LPC standards, we observed noticeably different fragmentation patterns of the
acyl chain, especially in the relative abundance of fragment ions C16H31 (m/z 223),
C14H29 (m/z 197), C14H27 (m/z 195), C13H27 (m/z 183), C13H25 (m/z 181), C8H15 (m/z 111), and
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C8H13 (m/z 109) (Fig. S3C). When T. cruzi C18:1-LPC (from ICA forms) was analyzed under
the same MS conditions, the fragmentation pattern observed was consistent with a Δ9 double
bond (Fig. S3C, bottom spectrum). The same type of experiment was conducted with T.
cruzi C18:2-LPC (from ICA forms) and the resulting fragmentation was consistent with
Δ9,12 double bonds (data not shown).
The POROS R1 protocol we have described here also enriched other LPC species, which
included C22:6-LPC (m/z 574), C22:4-LPC (m/z 578), C16:0-LPC (m/z 502), and C16:1-LPC
(m/z 500) that were also characterized by MSn (Fig. S4). Most of these species, except for C22:6LPC, had very low abundance and, in the case of Epi and Meta forms, could only be seen in the
enriched 25%-n-propanol POROS R1 fraction. Even for TCT and ICA forms, MS3and MS4 of
the C16:1-, C22:4- and C18:0-LPC species could only be conducted with samples derived from
the POROS R1 chromatography. This confirms that indeed this last fractionation step is
necessary for the full characterization of low-abundance LPC species from complex
phospholipid mixtures of T. cruzi. Using the current methodology, however, we were unable to
detect any bona fide PAF species in any of the four parasite stages analyzed. Even employing the
highly specific and sensitive MS approach, selective-ion monitoring (SIM), we could not detect
any trace amounts of PAF species in T. cruzi. This was true not only for the POROS R1 25% npropanol fractions, but for all fractions described in this study. Therefore, we surmise that if
there were any PAF species in this parasite, the concentration levels would likely be below the
detection limit of the MS approaches used in the present study.
After characterizing the different T. cruzi LPC species, we proceeded to quantify them
using a synthetic C10:0-LPC as an internal standard. These analyses were conducted on freshly
prepared parasite pellets to minimize the amount of time that T. cruzi phospholipases A1 and
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A2 ((104)) could have to act on PCs, leading therefore to an artificial increase in LPC levels.
Overall, the lipid profiles of freshly prepared pellets were nearly identical to the profiles of
previously frozen pellets of the same parasite forms (Figs. 4 and 7, and data not shown). The
LPC quantification showed that the amount of C16:0-, C18:0-, C18:1- and C18:2-LPC present in
the mammalian-dwelling forms of T. cruzi (ICA and TCT) were much higher than in the insectdwelling (Epi, Meta) forms (Table 1). For instance, although the two most abundant LPC
species found in all four parasite forms were C18:1- and C18:2-LPC, ICA forms had ~44 and
~35 times more of these species, respectively, than Epis. TCTs also showed very high levels of
these lipids, having approx. 16–17 times more C18:1- and C18:2 LPC than Epis (Table 1).
Interestingly, TCTs also contained the highest levels of C16:0-LPC, which has been shown to
have immunosuppressant activities in the context of T. cruzi infection ((46)).
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Figure 7: Quantification of LPC species in different life-cycle stages of T. cruzi.
C10:0-LPC (m/z 418) was used as an internal standard for quantification of the most abundant T. cruzi LPC species.
C10:0-LPC (18 nmoles) was added to all fresh parasite pellets prior to lipid extraction with C:M (2:1, v/v) and
C:M:W (1:2:0.8, v/v/v), followed by Folch’s partition. The Folch lower phase was analyzed by ESI-LIT-MSn. LPC
species are indicated in the spectra. Epi, epimastigote; Meta, metacyclic trypomastigote; ICA, intracellular
amastigote; TCT, tissue culture-derived trypomastigote. Picture taken from Gazos-Lopes et al, 2015,
neglected tropical diseases 8, e3077.
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Table 1. C18:2-, C18:1-, C18:0- and C16:0-LPC content in different life-cycle stages of T. cruzi.

Taken from Gazos-Lopes et al, 2015, PLoS neglected tropical diseases 8, e3077.
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To assess whether T. cruzi is also able to secrete LPC species to the extracellular milieu,
we analyzed extracellular vesicles (EVs) and EV-free supernatant or conditioned medium (VF)
of Epi and Meta forms, obtained as described ((90)). Epi and Meta forms secrete two types of
EVs, namely V2 and V16, which are vesicles obtained after 2 h and 16 h of ultracentrifugation
(at 100,000×g), respectively. In both stages, V2 are larger vesicles resembling ectosomes (130–
140 nm), whereas V16 are smaller vesicles resembling exosomes (70–90 nm). The final vesiclefree supernatant (VF) in both stages is virtually devoid of EVs ((90)). As shown in Table
S1 and Fig. S5, although Epis have higher amounts of C18:1- and C18:2-LPC than Metas in the
total parasite pellet, the latter secrete much higher amounts of these phospholipids in the EV-free
conditioned medium (mVF). Metas secrete 1.9 pmol of C18:1-LPC per 106 cells in mVF and an
additional 0.5 pmol associated with mV2 fraction. Similar values were found for C18:2-LPC in
mVF and mV2 (Table S1). In comparison, Epis only secrete trace amounts of both LPCs in eV2.
In our analyses, however, we were only able to detect trace amounts of C16:0-LPC in the V2,
V16, and VF fractions of Epis and Metas (data not shown). Taken together, our data strongly
indicate that C18:1-LPC, C18:2-LPC, and eventually other LPCs could actively be secreted by
Metas during the early stages of the infection. Moreover, LPCs secreted by these parasites could
contribute to the overall LPC pool in the plasma, saturating the lipid carrier proteins, and
eventually activating PAF receptors. Most importantly, the relative concentration of C18:1-LPC
could even be higher in the infected tissues, due to the continuous secretion of this phospholipid,
associated or not with parasite EVs. Owing to the technical difficulty in obtaining enough
parasites for preparation of EVs from TCTs or ICAs, we have not been able to conduct the same
kind of quantification in these mammal-dwelling stages.
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2.3.3 Effect of LPC species on the aggregation of rabbit platelets
Since we were unable to detect any PAF species in any of the four parasite stages
analyzed, we hypothesized that the PAF-like molecule could be one or more of the
lysophospholipids structurally characterized here. This assumption is also based on previous
reports that certain LPC species seem to activate the PAFR ((57), (105)). Moreover, purification
of sufficient amounts of each T. cruzi LPC species for the bioassay (i.e., platelet aggregation)
was not feasible. Therefore, we carried out the platelet aggregation assays using synthetic
(C16:0-, C18:0-, C18:1-, and C22:6-LPC, at 1, 10, 100, and 1000 µM) or purified (C18:2-LPC)
LPC species, and synthetic C16:0-PAF (at 1 µM; positive control). In a set of experiments
platelets were pre-incubated for 30 min in the presence of 10 µM WEB 2086. As seen in Fig. 8,
C16:0-LPC, C18:0-LPC, and C18:2-LPC failed to aggregate platelets at 10 µM, or at any other
concentrations used (data not shown). Interestingly, C18:1-LPC was able to aggregate rabbit
platelets at 10 and 100 µM (Fig. 8), but unlike PAF, failed to perform this activity at 1 µM (data
not shown). WEB 2086 completely abolished platelet aggregation induced by C16:0-PAF and
C18:1-LPC (at final concentrations of 1 µM and 100 µM, respectively) (Fig. 8). We were aware
of the fact that depending upon the acyl chain length and degree of unsaturation, high
concentrations (>30 µM) of LPCs could act as strong detergent and promote cell lysis ((63)).
Therefore, in our platelet aggregation assays, we used all LPCs at a maximal 10 µM
concentration, except for C18:1-LPC, which was also tested at 100 µM. We did not observe
platelet lysis up to 10 µM of any LPC tested, or even at 100 µM of C18:1-LPC
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Figure 8: Activity of C16:0-PAF and different T. cruzi LPC species on the aggregation of rabbit
platelets.Platelet aggregation assays were performed as described in Materials and Methods, using synthetic 16:0PAF and C16:0-, C18:0-, C18:1-LPC, and purified C18:2-LPC. Control platelets or platelets pre-treated for 30 min
with 10 mM WEB 2086 were assayed in the absence or presence of 1 mM C16:0-PAF or the LPC species at 10 mM
(C16:0-LPC, C18:0-LPC, C18:1-LPC, and C18:2-LPC) and 100 mM (C18:1-LPC). Each lipid was tested in
duplicate as indicated by black and blue curves in each graph. Picture taken from Gazos-Lopes et al, 2015, PLoS
neglected tropical diseases 8, e3077.
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2.3.4 Comparative modeling of the PAF receptor
To gain insights into the mechanism by which C18:1-LPC, but not C16:0, C18:0, C18:2,
could induce platelet aggregation mediated by PAFR, we decided to build a 3D-structural model
of the PAFR, since a high-quality model was not available in the literature. The structural
features of our PAFR model are shown in Figure 9A. As a member of the class A of GPCR
superfamily, the PAFR model encompasses an extracellular N-terminus, followed by seven
transmembrane (TM) α-helices (TM1, TM2, TM3, TM4, TM5, TM6, and TM7) (Fig. S6A),
connected by three extracellular loops (EL1, EL2, and EL3) (Fig. S6B) and three intracellular
cytoplasmic loops (CL1, CL2, and CL3) (Fig. S6C) and, finally, a short α-helix (H8) at the
intracellular C-terminus (Fig. 9A). Additionally, the spatial arrangement of the 7-TM bundle
constitutes a hydrophilic cavity covered by EL2, which is described as a ligand-binding pocket
(Figs. 9A and S6B) ((101), (106), (107), (108), (109), (110), (111)).

2.3.5 Structural validation of the PAFR model
The I-TASSER methodology is very accurate for the construction of protein models
when the sequence identity between the target sequence and the template protein drops below
30%, where lack of a high-quality structure match may provide substantial alignment errors and,
consequently, poor quality models. In addition, the I-TASSER methodology has already been
used for modeling other GPCRs ((101), (111)). The structural validation of the PAFR model was
performed using three programs: PROCHECK ((98)), ERRAT((99)), and PROQM ((100)). The
stereochemical quality of the PAFR model was evaluated using PROCHECK program.
According to an analysis of 118 known protein structures, a good quality model would be
expected to have over 90% in the most favored regions. The analysis of the first Ramachandran
plot revealed that 97.8% of the amino acid residues are located in the most favorable (92.0%)
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and additional allowed (5.8%) regions, confirming the excellent quality of the PAFR model
described here (Fig. S7). The analysis of the second Ramachandran plot, which considers only Φ
and ψ angles for Gly residues, showed that all 11 Gly residues in the primary sequence of PAFR
were in allowed regions, with favorable combinations of angles Φ and Ψ (Fig. S8). The
properties of the main and side chains for PAFR model were also evaluated by PROCHECK
program, which showed acceptable values for our model when compared to experimentallydetermined protein structures (Fig. S9 and S10). The analysis of distortions in the geometry of
the PAFR model residues was also analyzed using PROCHECK (Fig. S11). The parameters
analyzed were the bond lengths and angles, including atoms of the main and side chains, and the
results were considered acceptable for our PAFR model. In addition, we used the ERRAT
program for verifying errors in non-bonded atom-atom interactions in our model. The error
values are plotted as a function of the position of a sliding residue in the window ((99)).
According to this analysis, structures at high resolutions, generally produce values around 95%
or higher. However, for protein structures at lower resolutions (2.5 to 3 Å), the average overall
quality factor can be around 91%. The ERRAT analysis gave an overall quality factor value of
87% for our PAFR model (Fig. S12). Although low for crystal structures, this value is acceptable
for protein models ((100)). Finally, we analyzed the quality of the three-dimensional structure of
our model at local and global levels, using PROQM program ((99)) (Fig. S13). This program
uses a score function to evaluate structures of membrane proteins, including GPCRs ((100),
(112), (113)). Thus, to each residue of the protein model is given a score, producing,
consequently, an overall quality factor. The value of the overall quality factor generated by
server PROQM ranges from 0 to 1, indicating a model of poor and excellent quality, respectively
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((97)). The PROQM analysis gave a global quality score of 0.717 for our PAFR model (Fig.
S13), which is similar to the score values for crystallographic structures of GPCR ((99)).
2.3.6 Molecular docking
To compare the binding mode of all ligands (C16:0-PAF, and C16:0-, C18:0-, C18:1-,
and C18:2-LPC) to the PAFR model, we carried out ten docking simulations for each ligand
(totalizing 50 poses per ligand) and, consequently, the poses with the lowest energy for each
ligand was selected for analysis. The comparison between C16:0-PAF and each LPC species is
represented in Fig. 9B–E and Fig. S14. The molecular docking study showed that C18:1-LPC
and C16:0-PAF have similar modes of interaction with PAFR (Fig. 9D and Fig. S14C). On the
other hand, no other LPC species was able to interact with PAFR in a similar way, which
corroborates the platelet aggregation assays (Fig. 8). Since PAF and LPC have different
structures, RMSD matrix was not calculated. Instead, distances between the heteroatoms of the
functional groups (amino, phosphate, and acyl groups) of C16:0-PAF and all LPC species were
measured. The nitrogen of the amino group, the phosphorous of the phosphate group, and the
oxygen linking the glycerol backbone (at sn-1) to the carbonyl group of the acyl chain were
chosen and all distances between the ligands are presented in Table 2. The distances between
heteroatoms of C16:0-PAF and C18:1-LPC are clearly lower than the distances between C16:0PAF and other LPC species (C16:0, C18:0, and C18:2), with the exception of the amino group of
C18:2-LPC and C16:0-PAF, confirming the similarities between C16:0-PAF and C18:1-LPC
binding modes. The energy of the interactions between PAFR and each ligand was also analyzed
(Table 3). The hydrogen bonds and repulsive steric interactions were mapped using a ligandmap algorithm, generated by the MVD program ((101)). The hydrogen bonds are represented
in Figure 9. C16:0-PAF and C18:1-LPC interact with the same amino acids (i.e., Asn159 and
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Thr160) of the PAFR model. Other LPCs do not present the same pattern of interaction.
Interestingly, C18:1-LPC is able to additionally interact with Ser157, through its hydroxyl group,
in a very strong way (Fig. 10 and Table 3). Although C16:0-, C18:0-, and C18:2-LPC also form
hydrogen bonds with amino acids, these interactions occur in a different region of the PAFR
model and with lower strength. Finally, the amino group either of C16:0-PAF or any of the LPC
species did not seem to interact to our PAFR model (Fig. S15).
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Figure 9: Structural representation of the PAFR model and its interaction with PAF and LPC species.

(A) Side view of PAFR model. Each TM (alpha-helix) is indicated in a different color: TM1, blue; TM2, red; TM3,
dark gray; TM4, orange; TM5, yellow; TM6, purple; TM7, green. The helix 8 (H8) at the end of C-terminus region
is indicated (brown). (B–E) Comparison of binding modes of PAF and each LPC species to PAFR. (B) C16:0-PAF
(cyan) and C16:0-LPC (yellow); (C) C16:0-PAF (cyan) and C18:0-LPC (orange); (D) C16:0-PAF (cyan) and C18:1LPC (green); and (E) C16:0-PAF (cyan) and C18:2-LPC (pink). Transmembrane (TM) regions are represented as
white rods. Picture taken from Gazos-Lopes et al, 2015, PLoS neglected tropical diseases 8, e3077.
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Figure 10: Hydrogen bonds between different lysophospholipid ligands and PAFR.

Hydrogen bonds are represented by blue interrupted lines. (A) C16:0-PAF; (B) C16:0-LPC; (C) C18:0-LPC; (D)
C18:1-LPC; and (E) C18:2-LPC. Nitrogen atoms are shown in blue, oxygen in red, and ligand carbon chains are
filled with the specific color for each ligand: C16:0-PAF, cyan; C16:0-LPC, yellow; C18:0-LPC, orange; C18:1LPC, green; C18:2-LPC, pink. Picture taken from Gazos-Lopes et al, 2015, PLoS neglected tropical diseases 8,
e3077.
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Table 2. Distances between the amino, phosphate, and acyl functional groups of C16:0-PAF and
each LPC species.

Taken from Gazos-Lopes et al, 2015, PLoS neglected tropical diseases 8, e3077.

Table 3. Summary of the interactions of each ligand with the PAFR model.

Taken from Gazos-Lopes et al, 2015, PLoS neglected tropical diseases 8, e3077.
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2.4 Discussion
Previous results from our group showed that T. cruzi synthesizes a PAF-like phospholipid
capable of aggregating rabbit platelets ((73)). Aiming at the purification and structural
characterization of this putative PAF-like molecule, we developed a fractionation protocol that
proved efficient for the enrichment of PAF and other lysophospholipids such as LPAF and LPC.
Tandem MS and bioactivity data obtained in the present study revealed that the T. cruzi PAF-like
phospholipid is in fact an LPC, namely sn-1 C18:1(Δ9)-LPC. However, we do not discard the
possibility that very low amounts of a bona fide PAF species might still be synthesized by this
parasite. The MSn assignments for the C18:1-LPC we provide here are in agreement with
previous reports ((87), (89)), but somewhat different from the results obtained by Smith et
al. ((70)). Specifically, these authors analyzed a lipid species with a nearly identical
fragmentation pattern as what we have identified here as C18:1-LPC, but annotated it as a novel
C16:1-alkenyl-PAF. In their study, an ion species at m/z 265 was characterized as being derived
from the neutral loss of acetyl and methyl groups from the fragment ion at m/z 339. In addition, a
fragment ion atm/z 247 was proposed to be derived from the loss of water from the ion
at m/z 265. Conversely, we show here that the non-lithiated [R1CO+]+ and [R1CO+ H2O]+ fragment ions at m/z 265 and 247, respectively, are in fact derived from a C18:1-acyl
chain at the sn-1 position. This is further confirmed by the presence of lithiated ([R1CO2H+Li]+)
fragment ion from oleyl chain at m/z 289. Our assignments of C18:1-LPC are in complete
agreement with those reported by Hsu et al.((87)). Smith et al. ((70)) also proposed the ion
species at m/z 223 as being the protonated C16:1-alkenyl chain from the sn-1 position of that
putative PAF species. We also observed the same fragment ion in both synthetic and T. cruziderived C18:1-LPC, but we assigned it as derived from the fragmentation of the acyl chain.
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Taking all these facts into consideration, it is likely that Smith et al. ((70)) have mistakenly
identified C18:1-LPC as C16:1-PAF.
Here we show that T. cruzi synthesizes at least five species of LPC and that only sn-1
C18:1(Δ9)-LPC was able to promote rabbit platelet aggregation. These LPCs could be generated
by the action of host- and/or parasite-derived phospholipase(s) A1 and/or A2 on diacyl-PCs. A
PLA1 has already been well characterized in T. cruzi trypomastigote and amastigote forms (RA,
Cvd, and K98 strains) ((114), (115)),((116)). However, since we could only identify sn-1 C18:0-,
C18:1-, and C18:2-LPC, we believe that the parasite PLA1 is not playing a major role in the
generation of these LPCs, at least under the experimental conditions used in this study.
Nevertheless, we could not discard the possibility that the T. cruzi PLA1 might be important for
the generation of LPC species using different experimental conditions and/or other parasite
strains, as previously described ((114), (115)). Therefore, most likely the LPC species identified
in this study were generated by the action of a PLA2 from the host and/or parasite. No PLA2 has
so far been purified and fully characterized in T. cruzi, despite the fact that at least four putative
PLA2 genes have been annotated in the parasite genome (TriTrypDB TcCLB.510743.50,
TcCLB.510659.257, TCSYLVIO_005843, and Tc_MARK_4470) (104). Although a PLA2-like
activity has been previously reported in epimastigotes ((117)), no further characterization of this
enzymatic activity has been published. Moreover, using more rigorous enzymatic assay
conditions, Belauzaran et al. ((104)) were unable to detect any PLA2 activity in T.
cruzi epimastigote supernatants. This raises the possibility that the T. cruzi LPCs identified here
could have been generated by the action of a host-derived PLA2 and/or by a parasite-derived
enzyme that is expressed in much higher levels in the mammal-dwelling stages. Further studies
are needed to address this important point.
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A direct correlation between increased platelet reactivity and the incidence of acute
coronary diseases has been described ((118)). Accordingly, there is an increase in platelet
aggregation associated with ischemia, myonecrosis, and myocarditis in both acute and chronic
stages of Chagas disease ((10), (75), (11), (119)). Noteworthy, T. cruzi also synthesizes TXA2,
which modulates several pathophysiological aspects of Chagasic cardiomyopathy ((45)). It is not
surprising that T. cruzi produces at least two platelet activators, given the importance of platelet
aggregation in the progression of Chagas disease. Our bioactivity data with C18:1-LPC are in
agreement with other results in the present study, namely the platelet aggregation assays and
molecular docking predictions. We had also previously demonstrated that the putative PAF-like
phospholipid was able to trigger the differentiation of T. cruzi epimastigotes into metacyclic
trypomastigotes in vitro ((73)). This effect was abolished by WEB 2086, a classic competitive
PAF antagonist that binds specifically to PAF receptors ((120)). The latter result along with
labeling T. cruzi epimastigotes with polyclonal antibody raised against mouse PAFR, in
immunofluorescence assays, strongly indicated that T. cruzi might have putative PAFR both at
the cell surface and intracellularly ((73)). In fact, WEB 2086 inhibited all PAF effects upon
trypanosomatids described to date ((121), (122), (123)).
LPC has messenger functions, binding to a specific receptor and not acting through
physicochemical effects on the plasma membrane of the target cell. Several receptors for LPC,
such as G2A, GPR4, and IP, and receptors for TXA2 (TP) and PAF (PAFR), have been
described ( (53) , (54), (55), (56), (57), (58), (59), (60), (61)). In the present study, we show that
the platelet aggregation promoted by C18:1-LPC was abrogated by WEB 2086. This result is
highly suggestive that T. cruzi-C18:1-LPC may be able to trigger platelet stimulation through a
ligand-receptor system. Accordingly, LPC is known to induce intracellular signals ((124)) and
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mediate cytokine secretion ((62)), both through PAFR. Interestingly, the R. prolixus-derived
C16:0-LPC is able to prevent platelet aggregation triggered by PAF ((46), (48)). We may
hypothesize that C16:0-LPC acts as a PAF antagonist, binding to its receptor. Indeed, here we
show molecular docking calculations, which are suggestive that C16:0-, C18:0-, and C18:2-LPC
could be lodged within the ligand-binding site of PAFR, preventing PAF actions. On the other
hand, the predicted binding pose for C18:1-LPC evokes the possibility that this molecule and
C16:0-PAF exhibit similar modes of interaction with PAFR. These results can be partially
explained by the fact that, depending on the length and degree of unsaturation of the acyl-chain,
each LPC species triggers different cellular activities ((59), (63), (64)). Apparently, each of these
LPC species binds to different receptors, probably because of the tridimensional structure of
these phospholipids. For instance, TP receptors are involved in the attenuation of vascular
relaxation mediated by C18:2- and C20:4-LPC, but not C16:0- or C18:1-LPC ((59)).
Additionally, similar to C16:0-PAF, C18:1-LPC exhibited the ability to elicit a rapid, receptormediated oxidative burst, through generation of reactive oxygen species (ROS) in neutrophils.
On the other hand, C16:0- and C18:0-LPC did not share the same activity ((63)). Consistently,
our docking calculations show that both C16:0-PAF and C18:1-LPC structures interact with
PAFR model with Asn169 and Thr170 residues via hydrogen bonds. These amino acid residues
are localized at the extracellular loop EL2, which is involved in the ligand recognition and
receptor activation in the superfamily of the GPCRs ((125)). The number and the chain length of
the fatty acids of lipoproteins are also substantially important for the induction of signaling
through Toll-like receptor 2 (TLR2) ((126)). A cross-talk between TLR and GPCR has been
described, which is essential for cellular signaling in the absence of TLR natural ligands. This
cross-talk is basically a molecular organizational GPCR signaling platform that promotes the
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transactivation of TLR, through potentiation of Neuraminidase 1 and matrix metalloproteinase-9
at the cell surface ((127)). Intriguingly, LPC derived from the human pathogen Schistosoma
mansoni activates TLR-2-dependent signaling involved in eosinophil activation and recruitment,
probably through cross-talk to a GPCR ((128)). More recently, we have shown that various
species of LPC containing different acyl chain lengths and degrees of unsaturation may induce
proinflammatory response mediated by TLR4- or TLR2/TLR1-dependent signaling pathway in
HEK293A cells ((129)). Interestingly, a mixture of LPC species (mainly C16:0- and C18:0-LPC)
could

counteract

TLR4-mediated

signaling

pathway

triggered

by E.

coli O111:B4

lipopolysaccharide (LPS), suggesting therefore a dual role of this lysophospholipid in
immunoregulation.
Over time, LPC was found not to be exclusively of mammalian origin and was described
in several other organisms ((130)). Trypanosomatids tend to be rich in PC and LPC ((65), (66),
(67), (68), (131)). However, in most of these cases, the presence of LPC has only been inferred
indirectly and there still remains a general lack of information in the literature regarding the
chemical structure and function of the LPC species in most organisms other than mammals. The
results described in the present study show that T. cruzi is able to generate different LPC species
and suggest that the levels of individual LPC species are tightly regulated in the course of this
parasite cell cycle. In fact, the LPC levels are notably high in the mammal-dwelling infectious
trypomastigote and intracellular amastigote stages. Taken together with the fact that there was no
exogenous source (e.g., fetal bovine serum) of lipids in the TAU culture medium used for the
differentiation of epimastigotes into metacyclic trypomastigotes, our data indicate that LPC
species might be generated endogenously by this organism.
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The saliva of R. prolixus is a source of LPC, which may act as an enhancing factor for
Chagas disease ((46), (47)) LPC, TXA2, and PAF are lipid mediators that share a common
chemical structure, biosynthetic pathways ((132)) and the ability to activate platelets ((133),
(134), (135)). Previous results from our group have shown that PAF-treated T. cruzi is far more
infective towards both mouse macrophages ((73)) and the insect vector R. prolixus ((136), (137))
TXA2 synthesized by T. cruzi controls the proliferation of the parasite and resulting
inflammatory response to infection in the mouse ((45)). One may then speculate that host-vectorparasite co-evolutionary relationships may be involved in the maintenance or change in the
enzymatic pathways for the synthesis and degradation of these molecules, which ultimately may
dictate the success of T. cruzi infection.
In conclusion, here we demonstrate that T. cruzi synthesizes at least five LPC species,
C16:0-, C18:0, C18:1-, C18:2-, and C22:6-LPC. The most abundant species are C18:2- and
C18:1-LPC, being the latter the only one able to aggregate rabbit platelets, probably through a
PAFR. This result was supported by molecular docking study of the interactions between LPC
species and a PAFR model. These analyses showed that C18:1-LPC was able to interact with the
PAFR model in a fashion similar to PAF. More studies on LPC metabolism in T. cruzi and
relationship of the parasite with the mammalian and invertebrate hosts could, therefore, lead to
the discovery of putative targets for novel therapies and control for Chagas disease.
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3. CHAPTER 3: GPIOMIC ANALYSIS OF THE MAMMALDWELLING STAGES OF TRYPANOSOMA CRUZI

3.1

Introduction

3.1.1 GPI-anchor structure and function
Glycosylphosphatidylinositols (GPIs) are a class of protein post-translational
modification (PTM) ubiquitously found in eukaryotes. Both GPI-anchored proteins (GPI-APs)
and protein-free GPIs, known as glycoinositolphospholipids (GIPLs), are involved in diverse
biological events, which include signal transduction, embryological development, immune
responses, cell-cell interactions, plant development, and the survival/virulence of several
pathogens (9,12,138-146).
The core structure of GPIs is highly conserved, consisting of an inositolphospholipid
moiety covalently attached to a conserved carbohydrate core (Manα1-2Manα1-6Manα14GlcNα1-6-myo-inositol1-HPO4--lipid) (147). The lipid portion of the anchor is immersed in the
outer leaflet of the plasma membrane, whereas the glycan portion projects outward, facing the
extracellular environment. A single GPI can be attached to a protein via an amide linkage formed
between the carboxyl group at the C-terminus of the protein and the amino group of either an
ethanolamine phosphate (EtNP) or an aminoethylphosphonate (AEP) moiety present at the third
mannose residue distal from the glucosamine (GlcN) residue of the conserved GPI glycan core
(Fig. 11A) (141-145,147). Variations on the structure of the lipid moiety, as well as the addition
of different side-chains to the glycan core of GPIs, greatly increase the potential diversity of
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these molecules. In fact, a single cell may contain dozens of different GPI structures, with each
of them potentially exhibiting different biological activities (139,142).

Figure 11: GPI-APs and GIPLs. (A) The core structure of GPI consists of an inositolphospholipid bound to a
conserved glycan chain (Manα1-2Manα1-6Manα1-4GlcNα1-6myoinositol1-PO4-lipid). Proteins can be covalently
linked to this anchor through a peptide bound between an EtNP or AEP substituent present at the third mannose
residue of the GPI distal from the glucosamine (GN) residue and the carboxyl group at the C-terminus of the protein.
(B) The surface of T. cruzi is densely packed with GIPLs and GPI-APs (mostly mucins, MASPs, and transsialidases/gp85 glycoproteins) (141,143)
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General interest in these molecules started with the description of the first GPI-anchor,
which was discovered in Trypanosoma brucei (148). In this seminal work, it was shown that the
main surface antigen of T. brucei, known as variable surface glycoprotein (VSG), was anchored
to the parasite’s plasma membrane by a new class of glycolipid, now known as GPI (148-151).
Since then, many studies have described the effects of different trypanosomatid-derived GPI-APs
and GIPLs on the immune system of vertebrates, with emphasis on mammals (143,152-154).
These studies were not limited to trypanosomatid parasites, and many of them have also been
performed on other important parasite models, such as Plasmodium falciparum (155,156) and
Toxoplasma gondii (157).
It has been shown that GPI-APs and GIPLs cover most of the surface of T. cruzi, with
every parasite having an estimated 2 x 106 and 2 x 107 copies of GPI-APs and GIPLs,
respectively, on its surface (Fig. 11B). This observation is in agreement with findings that show
that trypanosomatids make use of bioactive GIPLs and GPI-APs to successfully modulate the
host immune system and to invade host cells. In general, parasite-derived GPI-APs and GIPLs
lead to an increase in the circulating levels of proinflammatory cytokines and chemokines, the
expression of nitric oxide synthase II, and the expression of macrophage adhesion molecules. It
has also been shown that GPIs are required for amastigote development in host cells, without
which they cannot sustain chronic infection (138,140,141,143-145,153,158,159). Various studies
also indicate that these molecules activate host innate immunity, which is responsible for
controlling acute Cd (140,141,154,158,160,161).
Although there still is very little information regarding the effects that parasite GIPLs and
GPI-APs have on insect vectors, it is clear that a series of parasite-specific structures are
associated with their ability to successfully colonize their vectors (162,163). In many cases, the

54

insect-dwelling parasite forms make use of certain GPI structural features, such as the presence
of beta-galactofuranosyl (β-Galf) residues, in order to specifically bind to lectins present on the
insect vector midgut, allowing them to colonize this compartment (162-165). Parasite-derived
GIPLs are also able to modulate vector immune responses, as well as their feeding efficiency,
potentiating transmission to hosts (155,156,166,167). These effects are normally species and lifecycle stage specific. For this reason, different life-stages of a same parasite species will exhibit
very different GPI-AP and GIPL structures, as they adapt to either colonize their insect-vector or
to infect their mammalian hosts (79,167,168).
In spite of the importance of GIPLs and GPI-APs to the biology of T. cruzi, a better
understanding of the mechanisms behind their contribution to parasite survival and virulence has
been partially hampered because of the difficulties involved in the structural characterization of
these molecules using more traditional approaches. This made the large-scale analysis of GIPLs
and GPI-APs unfeasible. Our group has described a novel approach (i.e., GPIomics) for the
large-scale analysis of GPIs and GIPLs by liquid chromatography-electron spray ionizationtandem mass spectrometry (LC-ESI-MS/MS) (138). With this approach we were able to identify
96 GPI species derived from the non-infective epimastigote stage, 79 of which were formerly
unknown. Because epimastigotes are non-infective to humans, it is crucial to describe the
GPIome of the mammal-dwelling stages of this parasite, so that this information can be explored
in future studies regarding the effects of these molecules during infection and how to target them
in the development of new therapies for Chagas disease. In fact, parasite GPIs have been
validated as potential therapeutic targets in human African trypanosomiasis (169-174) and
malaria (175). Here, we report the first large-scale analysis of the GPIome of the mammaldwelling stages of T. cruzi.

55

3.1.2

GPI anchor Biosynthesis in Trypanosomatids

As mentioned on the section above, the core structure of GPIs has been conserved
throughout evolution. This suggests that the GPI biosynthetic machinery of different eukaryotic
clades is also relatively conserved. Most of the studies pertaining to the biosynthesis of GPIs
have been conducted in mammals, yeast, and T. brucei (143,144,154,176,177). Because T.
brucei is closely related to T. cruzi, these two species could have similar GPI biosynthetic
pathways.
The first step in the GPI biosynthetic pathway of any known model is the transfer of Nacetylglucosamine (GlcNAc) from UDP-GlcNAc to a PI acceptor through the action of a
GlcNAc-transferase complex present at the cytoplasmic side of the endoplasmic reticulum (ER)
(178,179). The GlcNAc-PI is then deacetylated by a de-N-acetylase, giving rise to GlcN-PI (180182). Next, the GlcN-PI is flipped to the luminal side of the ER, where it is mannosylated by a
dolichol-phosphate-mannose transferase: GlcN-PI α1-4 mannosyltransferase (MT-I). This is
followed by the acylation (usually with a palmitic acid) of the 2-position of the myo-inositol ring
by an inositol acyltransferase (143).
The next step in the biosynthesis of GPIs in T. brucei is the transfer of a second mannose
residue to the GPI precursor through the action of a dolichol-phosphate-mannose transferase:
Man1GlcN-(acyl)PIα1-6mannosyltransferase (MT-II), which has not been described in any
organism. The third mannose residue of the conserved glycan core is added by a dolicholphosphate-mannose transferase: Man2GlcN-(acyl)PI α1-2 mannosyltransferase (MT-III) (143).
An EtNP residue is then added to the position 6 of the third mannose residue through the activity
of an ethanolamine phosphotransferase (183). The product of this enzyme is usually deacylated
by an inositol deacylase, giving rise to the conserved “mature” core ([EtNP]Manα1-2Manα156

6Manα1-4GlcNα1-6myo-inositol1-HPO4--lipid). After the glycan core is formed, the T. brucei
GPI precursor is further modified by a lipid exchange process known as “GPI-lipid remodeling”
(184). While most GPI intermediates in this species have sn-1-stearoyl (C18:0)-2-acyl-PI
moieties, its mature GPIs have almost exclusively dimyristoyl (C14:0) moieties, which are
generated through ordered deacylation and reacylation reactions (143,150,151,185). Several
enzymes involved in the biosynthesis of GPIs in T. brucei have not yet been described in detail,
and it is possible that many of the activities mentioned above are realized by the same enzymatic
complex. After the GPI anchor is synthesized, it is attached to the C-terminus of a protein
precursor by a GPI transamidase complex (GPI-TA). This enzyme recognizes and cleaves a
signal sequence present at the C-terminus of a protein and replaces it with the mature GPI anchor
(186,187). The GPI-AP is then transported to the Golgi complex, where the GPI anchor can be
further modified through the addition of other sugar residues to the glycan core via the activity of
different GPI glycosyltransferases. After processing in the Golgi complex, the GPI-AP or the
protein-free GPI (or GIPL) is transported to the plasma membrane (Fig. 12) (188).
Although the GPI biosynthetic pathway in mammalian cells is very similar to the one
described in T. brucei, a few crucial steps differ greatly between these two models
(143,144,188). The first difference is that mammalian cells acylate the myo-inositol ring prior to
the addition of the first mannose residue to the nascent GPI precursor (143,144). The second
difference is that in mammals the lipid remodeling only occurs after the GPI-AP is transported to
the Golgi complex (144,188). In some cases, this remodeling does not occur at all, as is the case
of erythrocytes. The third difference, is that proper GPI-AP assembly is dependent on the
sequential addition of an EtNP residue to the first and third mannose residues of the GPI
precursor before the transamidase complex can attach the mature GPI to a proprotein (188,189)
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(Fig. 12). Although the GPI-TA always attaches GPIs to proteins via the EtNP residue at the
third mannose residue, it appears that in mammals the presence of an EtNP residue on the first
mannose residue is necessary for efficient GPI-anchoring to occur. Mutants that do not express
the enzyme responsible for the addition of this first EtNP (PIG-N) are unable to efficiently
perform GPI-anchoring (189). Finally, in mammals the attachment of an EtNP residue to the
second mannose residue of the mature GPI-AP is necessary for it to concentrate at the ER-exit
site (ERES), where they will be transported to the Golgi complex by COP II vesicles. Cells
defective on the enzyme responsible for the addition of this modification tend to accumulate
GPI-APs indefinitely at the ER (188,190). The addition of the EtNP residue to the second
mannose residue of the GPI-AP is transient, since this modification is removed prior to transport
out of the ER. It is possible that the addition of this modification acts as part of a quality control
mechanism that somehow recognizes and only allows mature GPI-APs to be transported to the
Golgi complex. In this sense, the addition and removal of this modification would be necessary
for a GPI-AP to be considered mature and, consequently, ready to be transported out of the ER
(188-191).
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Figure 12: The GPI biosynthetic pathways in T. brucei (A) and in mammalian cells (B). The major steps
involved in the GPI biosynthesis in both models are described in the body of the text above. Figure modified
from (143)

3.1.3 AEP biosynthesis and degradation
One of the most intriguing characteristics of T. cruzi GIPLs and GPI-APs is the fact that
they are usually modified by AEP residue(s), instead of the more common EtNP (79,138,192194). Curiously, the only three other species known to add AEP to their GPIs, namely
Trypanosoma dionisii (195), Leptomonas samueli (196), and Herpetomonas samuelpessoai
(197), belong to the class Kinetoplastida. Interestingly, as aforementioned, other important
Kinetoplastid parasites such as Leishmania spp. and T. brucei do not add AEP to their GPIs,
relying on EtNP like the majority of eukaryotes.
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Although EtNP and AEP are structurally very similar, AEP contains a very unusual
phosphonate bond (-H2C‒PO3-2), instead of the common phosphate ester bond (-H2C‒O‒PO3-2).
The phosphonate bond is highly stable and is not a substrate for enzymes that recognize
molecules containing phosphate ester bond bond, such as phosphotransferases. This means that
molecules containing phosphonate bonds belong to a separate metabolic pool from the ones that
contain phosphate ester bonds, effectively participating in very different biological processes
(198).
Phosphonates are not usually synthesized in appreciable quantities by vertebrates, being
more commonly found in marine invertebrates and bacteria (198). AEP is the most abundant
phosphonate in living systems, being found as a conjugate of lipids (199), proteins (200), and
glycans (201). The biosynthesis of this molecule usually starts with the conversion of
phosphoenolpyruvate (PEP) to phosphonopyruvate (P-pyr) through the action of a
phosphoenolpyruvate

mutase

(PEP

mutase).

This

product

is

then

converted

to

phosphonoaldehyde (P-Ald) by a P-pyr decarboxylase. This step is rate-limiting for the
maintenance of phosphonate homeostasis, since PEP mutase is more efficient at converting P-pyr
to PEP then at performing the opposite reaction. The final step of this pathway is the conversion
of P-Ald to AEP through the activity of an AEP transaminase (AEPT). This enzyme is also
responsible for converting AEP back to P-Ald, which is then broken down into inorganic
phosphate and acetaldehyde by a phosphonatase in the AEP biodegradation pathway (Fig. 13)
(198,202).
The only enzyme involved in AEP metabolism to have been described in T. cruzi is the
PEP mutase, which was shown to have a very similar sequence as to the homologous gene in the
protozoan Tetrahymena pyriformis, and the mussel Mytilus edulis. This enzyme appears to be
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arranged as a homotetramer, and to be localized to an as-yet unidentified organelle (203). Most
studies describing AEPT structure and activity have been performed in bacteria, such as
Pseudomonas aeruginosa (204), and in certain protozoa, such as T. pyriformis (205). The active
site and overall fold of AEPTs appear to be relatively conserved, although the pH and
temperature optima for this enzyme vary greatly across different species (202-207).
The fact that most T. cruzi GIPLs described to date contain an AEP residue attached to
the O-6 position of the GlcN residue at the conserved glycan core suggests that this modification
has an important function for this species (192-194). It is possible that this modification plays an
analogous role to the addition of EtNP to the second mannose residue of nascent GPI-APs in
mammalian models (144). In this case, the addition of AEP to the hexosamine residue could be
part of a quality control mechanism that would only allow mature GPI-APs and GIPLs to exit the
ER in this organism. Because of its potential relevance for GPI biosynthesis and transport in T.
cruzi, and the fact that the AEP biosynthetic pathway is not found in humans, AEPT might be a
good candidate for the development of new chemotherapeutics against this parasite. Therefore,
one of our objectives is to verify whether GPI-APs and GIPLs derived from the mammaldwelling stages of T. cruzi are as frequently modified with AEP as reported for the GPIome of
Epis (138)
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Figure 13: The conserved pathways for AEP synthesis and degradation: All major steps have been described on
the text above. AEP, 2-aminoethylphosphonate; PEP, Phosphoenolpyruvate; P-Ald, Phosphonoaldehyde. Figure
taken from (202)
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3.2 Materials and Methods
3.2.1 – Chemicals
Otherwise indicated, all reagents and solvents used here were of analytical, HPLC, or
mass spectrometric grade from Sigma-Aldrich (St. Louis, MO).5,h5

3.2.2 - Trypanosoma cruzi cultures
All T. cruzi life cycle stages or forms were obtained from the Y strain (76). Epimastigote
forms (Epis) were maintained by weekly transfers using liver infusion tryptose (LIT)
medium (77), supplemented with 0.002% hemin and 10% heat-inactivated fetal calf serum (FCS;
Hyclone, heat-inactivated at 56°C for 30 min) at 28°C. Mammalian tissue culture-derived
trypomastigotes (TCTs) were obtained from the supernatants of 5 to 6 days old T. cruzi-infected
LLC-MK2 cells (American Type Culture Collection, Rockville, MD), maintained in RPMI-1640
medium supplemented with 2% FCS at 37°C in a 5% humidified CO2 atmosphere (80).
Intracellular amastigotes (ICAs) were obtained as described (81). Briefly, infected monolayers of
LLC-MK2 cells were gently detached by scraping (BD Falcon cell scraper, BD Biosciences) and
resuspended in PBS supplemented with 10% FCS. Mammalian cells were disrupted by passage
through a 27-gauge needle (BD, Becton and Dickinson & Co.). ICA forms were separated from
the cell debris by centrifugation (800× g for 5 min at 4°C). The supernatant was then harvested
and passed through a DE-52 column and parasites were incubated for 2 h at 37°C in a humidified
5% CO2 atmosphere, after which the parasites were again passed through a DE-52 column, from
which they were harvested and stored. For the viability testing of all parasite forms, cells were
resuspended in a Trypan Blue solution and counted in a Neubauer chamber (82). In this study, all
experiments were performed using parasites that were harvested by centrifugation and washed
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three times with PBS before use, unless otherwise specified. All parasite forms were counted and
stored at -20 oC prior to use.

3.2.3 - Extraction of GIPLs and GPI-APs
Epi, TCT, or ICA pellets (1 x 109 parasites each), were suspended in 0.8-ml of ice-cold
HPLC-grade water, and transferred to 8-mL PYREXR culture tubes with PTFE-lined screw caps.
HPLC-grade chloroform and methanol were added to each vial, giving rise to a final ratio of
chloroform/methanol/water (C/M/W) of 1:2:0.8 (v/v/v) (3.8 mL). The samples were mixed
thoroughly by vortexing for 2 min, and then centrifuged for 10 min at 1,800 x g at room
temperature. After centrifugation, the supernatants were transferred to 8-mL PYREXR culture
tubes and the pellets dried under a constant flow of N2 stream. The dry pellets were extracted
three times with C/M (2:1, v/v) (3 mL) and another two times with C/M/W (1:2:0.8, v/v/v) (3.8
mL), according to Bligh and Dyer (84). After extraction, the dried supernatants were pooled
together and subjected to Folch’s partitioning (83,84), being first dissolved in C/M/W (4:2:1.5,
v/v/v) (7.5 mL), then mixed vigorously for 5 min using a vortex and, finally, centrifuged for 15
min at 1,800 x g at room temperature. After centrifugation, the lower (organic) and upper
(aqueous) phases were separated into new 8-mL PYREXR culture tubes. The remaining
delipidated pellets were extracted again with 4 ml 9% n-butanol, as previously described (140).
The Folch aqueous phase (rich in GIPLs) and the 9% n-butanol phase (rich in GPI-APs) were
then dried and stored at -80oC until further use.
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3.2.4 - Digestion of GPI-APs with proteinase K
The GPI-AP fractions (9% n-propanol) were digested overnight at 37 0C with proteinase
K (30 units/mg protein, Tritirachium album, BioUltra) in 100 mM ammonium bicarbonate, pH
8.0. The digested samples (from here on referred to as GPIs) were suspended in 5% 1-propanol
and purified in POROS R1 50 (Applied Biosystems) solid-phase cartridges. Each column was
first conditioned with the sequential addition of methanol, 80%, 10%, and 5% 1-propanol and,
after sample application, the column was sequentially washed with 5% and 10% 1-propanol.
Finally, the GPIs were eluted with 80% 1-propanol. The last fraction (80% 1-propanol) was
analyzed by LC-ESI-MS/MS, along with the Folch aqueous phase (containing over 90% of all
GIPLs) (138).

3.2.5- LC-ESI-MS/MS of GIPL and GPI samples
The methodology used here is a modified version of the original GPIomics protocol
developed by Nakayasu et al. (138). Briefly, nanocapillary columns (75-µm internal diameter by
10-cm length) were packed in-house with a suspension of 10 mg/ml POROS R1 10 resin
(polystyrene-divinylbenzene beads, 10-μm particle size, Applied Biosystems) in 100%
acetonitrile (ACN) at 500 psi, with the help of a high-pressure column-packing apparatus. The
samples were dissolved in 20% 2-propanol/0.2% formic acid (FA), and loaded into a
nanocapillary column connected to a nanoHPLC system (UltiMate® 3000 Nano LC, Dionex).
The samples were eluted with a gradient of 20-80% 2-propanol containing 0.2% FA in the course
of 90 min at a flow rate of 500 nL/min. Because of loading, conditioning, and washing steps, the
total time for each step was 30 min (120 min total). The eluted molecules were directly analyzed
in a Hybrid Quadrupole-Orbitrap mass spectrometer (Q-ExactiveTM, Thermo Fisher Scientiﬁc)
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with a nanoelectrospray source (Nanospray FlexTM, Thermo Fischer Scientific). Full MS scans
were collected in positive-ion mode at the 400-1500 m/z range. The five most abundant ions
from the survey scans (70,000 resolution) were selected for data-dependent fragmentation using
higher energy collisional dissociation-type (HCD-type) fragmentation with a normalized
collision energy (NCE) of 15 and a maximum injection time of 100 ms. Whenever a dynamic ion
exclusion function was applied, it was set to collect each ion twice before it was excluded for 15
s, using an isolation window of 4-Th. The resolution of HCD spectra was set to 17,000. A
flowchart summarizing the different steps involved in the GPIomics approach is provided bellow
(Fig. 14).

3.2.6 - Structural assignment and relative quantification of GIPL and GPI
species
All MS/MS spectra corresponding to different GIPL or GPI species were annotated
manually, as described (138). Individual parent ions were plotted as extracted-ion
chromatograms, and the resulting peaks were smoothed 7 times with the Gaussian method, using
the Xcalibur software (Thermo Fisher Scientific). The relative quantification of different GIPL
and GPI species was performed by comparing the area of the peak corresponding to each species
to the sum of all areas corresponding to every species identified in each run. Results are
expressed as percentage of total.
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3.2.7 - GIPL and GPI monosaccharide compositional analysis
The GIPL and GPI monosaccharide compositional analysis was performed essentially as
described by Ferguson (208). Briefly, one end of heat-cleaned 100-µl glass capillary tubes
(Sigma-Aldrich) was flame-sealed with the aid of a small commercially available blowtorch.
Each sample was pre-mixed with 1 nmol scyllo-inositol internal standard and dried in a vacuum
centrifuge concentrator (Centrivap, Labconco). Twenty microliters of dry methanol were added
to each sample and the mixture was dried again. The dehydrated samples were diluted in 50 µl
0.5 M HCl in dry methanol (Supelco, Sigma-Aldrich) and the glass tubes heat-sealed under
vacuum. Then, the sealed tubes were placed in a heating block at 85°C for 4 h. The methanolysis
was interrupted by breaking open one side of each tube and adding 10 µl pyridine to neutralize
the HCl. Any free primary amines were N-acetylated through the addition of acetic anhydride.
The samples were then dried on a Centrivap, diluted again in 20 µl methanol, and dried for a last
time. After methanolysis, the samples were derivatized with trimethylsilanol (TMS) for 10 min
through

the

addition

of

15

hexamethyldisilazane:trimethylchlorosilane:pyridine

µl

of

(1.5:0.5:10

a
v/v/v).

mixture

of

The

gas

chromatography-mass spectrometry (GC-MS) analysis was performed with a SE-54 column (30
m x 0.25 mm x 0.5 mm, Fisher Scientific) on a Trace GC (Thermo Fisher Scientific, Austin, TX)
with the following running conditions: 140°C (2 min); 5°C/min gradient; 250°C (10 min)
intermediate temperature; 15°C/min gradient II with a final temperature of 265°C/min (5 min).
The carrier gas was helium, with a constant flow rate of 1.5 ml/min. The molecules were ionized
by electron impact at 70 eV. Mass spectra acquisition was performed with a linear scanning at
the 40-650 m/z range (Polaris Q, Thermo Fisher Scientific). Each sample was run at least three
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times, and the sugar residues identified with the help of a monosaccharide standard mix, which
were derivatized at the same time and under the exact conditions as the samples (209).

3.2.8 - Trypsin digestion of GPI-APs
After protein quantification, one mg of soluble proteins were precipitated with 10%
trichloroacetic acid for 20 min in an ice bath, centrifuged at 16,000 xg for 20 min at 4°C, washed
with ice-cold acetone, and dried in a vacuum centrifuge. Proteins were redissolved in 200 ul 0.4
M NH4HCO3 containing 8 M urea, and disulfide bounds were reduced with 5 mM dithiothreitol
(DTT) for 15 min at 50°C. Then, cysteine residues were alkylated with 10 mM iodoacetamide
(IA) for 30 min at room temperature, protected from light. Proteins were were digested with 20
μg sequencing-grade trypsin (Promega) for 24 h at 37°C. The reaction was stopped by the
addition of 10 μL formic acid (FA). Peptides were then desalted in a C18-solid phase extraction
cartridge (1 mL, Discovery DSC-18, Supelco, Sigma-Aldrich). The cartridge was activated with
4 mL methanol and equilibrated with 4 mL 0.05% trifluoroacetic acid (TFA). After loading and
washing with 4 mL 0.05% TFA, the sample was eluted with 2 mL 80% ACN/0.05% TFA and
dried in a vacuum centrifuge (Eppendorf).
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3.3 Results
3.3.1 LC-ESI-MS/MS analysis of GIPLs and GIPs
Although the original GPIomics method was developed using an LTQXL ESI-linear ion
trap-MS (ESI-LIT-MS) (Thermo Fisher Scientific) instrument, we conducted the current study
using a Hybrid Quadrupole-Orbitrap mass spectrometer (Q-ExactiveTM, Thermo Fisher
Scientiﬁc). This decision was based on the fact that the newer generation Hybrid QuadrupoleOrbitrap mass spectrometer outperforms the older LTQXL ESI-linear ion trap-MS because of the
superior resolution and sensitivity observed for this type of instrument (210). The nano-HPLC
system used was also changed from the 1D-Plus (Eksigent) to the newer UltiMate® 3000 Nano
LC (Dionex) for similar reasons. We, therefore, included previously analyzed epimastigotederived GPIs and GIPLs (eGPIs and eGIPLs, respectively) (138) to our analyses as a control.
In agreement with the original GPIomics work (138), we found that under the new
experimental conditions GPIs and GIPLs also gave rise to predominantly doubly-charged ions
([M + 2H]2+) in positive-ion mode ESI-MS in the presence of FA. With this information, we
were able to filter our full MS scans using the neutral loss of -81 m/z (corresponding to the
neutral loss of a hexose residue from a doubly-charged molecule). The neutral loss
chromatograms showed that the UltiMate® 3000 Nano LC system provided for a good peak
resolution, as exemplified in Fig. 15. Similar to what we had previously described, the POROS
R1 resin led to the separation of the GIPL and GPI species based mostly on the hydrophobicity
of their lipid moieties. Consequently, the species were resolved as “clusters” of peaks of similar
retention times based on the length and number of unsaturations of their lipid moieties. Species
containing either lyso-acyl- or lyso-alkylglycerol moieties eluted first, followed by species
containing small ceramide (Cer) moieties. The next species to elute contained alkylacylglycerol
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(AAG) moieties, and the last cluster of molecules to elute contained longer Cer moieties. As the
molecules eluted from the column, they were immediately analyzed by full Scan-MS/MS (Figs.
14 and 15).

Figure 14: Schematic representation of the GPIomics methodology.
GPI-APs and GIPLs were extracted and processed as described in the Materials and Methods section. After
extraction, GPI-APs digested with proteinase K and the Folch aqueous phase GIPLs were loaded into a POROS R1
column, and eluted with a 2-propanol gradient in the presence of 0.2% FA. The eluted samples were then analyzed
by ESI-MS/MS in a Q-Exactive Hybrid Quadrupole-Orbitrap mass spectrometer. Acquired spectra were annotated
manually. GPI-AP trypsin digests were processed and analyzed using a proteomics pipeline.
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Figure 15: Representative chromatogram of ICA GIPLs.
T. cruzi ICA aqueous Folch phase GIPLs were extracted and subjected to LC-MSn, following the steps described in
the Materials and Methods section. The acquired data was plotted for the neutral loss of hexoses from a doublycharged parent ion (neutral loss of -81 m/z). Alkylacyl-Gro, Alkylacylglycerol; Cer, ceramide; lyso-Acyl/AlkylGro, lyso-Acyl- or lyso-alkylglycerol.

71

We next proceeded to carry out the manual annotation of all GIPL species found in the
Folch upper phase (exemplified in Fig. 16) and of all GPIs found in the 9% n-butanol phase
(exemplified in Fig. 17) of Epis, ICAs and TCTs. The HCD-type fragmentation of the doublycharged ([M + 2H]+2) GIPL parent‐ions gave rise to fragments corresponding to the loss of the
lipid moiety (usually either AAG or Cer), and to two series of ions corresponding to the neutral
loss of multiple (usually n=1–6) hexose (Hex) residues. One of these series corresponds to the
sequential loss of Hex residues from the doubly-charged parent ion (sequential loss of -81 m/z
units), and the other series arises from to the sequential loss of Hex residues from the singlycharged ([M + H]+) glycan moiety (sequential loss of -162 m/z units). Also of interest is the
presence of a fragment at m/z 529.12, which corresponds to the myo-inositolphosphate (InsP)
attached to the hexosamine (HexN) residue covalently bound to an aminoethylphosphonate
(AEP) residue (AEP‐HexN‐InsP). Interestingly, unlike what we had described in Epis (138),
most of the GIPL species derived from ICAs or TCTs had only one AEP residue (attached to
HexN), instead of having either an additional AEP or an EtNP residue attached to a Hex residue
(Fig. 17). Because of the Q-Exactive’s high resolution, we were able to identify the lipid moiety
with high confidence using MS2 fragmentation alone. This identification was based on the
presence of an abundant fragment-ion corresponding to a dehydrated lipid moiety, as well as to
the presence of other fragments of this moiety, which can be observed in the lower ranges of the
spectra (Fig. 16).
In general, doubly-charged GPIs gave rise to similar fragmentation patterns as to the ones
described for GIPLs. The major difference between the MS2 spectra derived from GPIs, as
compared to the MS2 spectra derived from GIPLs, comes from the fact that most GPIs have an
EtNP residue attached to one of the Hex residues present on their glycan moieties. This gives rise
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to a predominant fragment series corresponding to either an EtNP or AEP attached to multiple
Hex residues (n=1-5). The dominant fragment in these series corresponds to either [(EtNP)Hex2
+ H]+ (m/z 448.12) or to [(AEP)Hex2 + H]+ (m/z 432.12) (Fig. 17). These differences, however,
are only observed in the mammal-dwelling ICA and TCT stages of the parasite, since we have
confirmed previous observations that eGIPLs and eGPIs tend to nearly always have either an
EtNP or an AEP residue linked to their glycan moieties (138).
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Figure 16: Representative annotated tandem MS spectrum of a T. cruzi trypomastigote GIPL.
T. cruzi GIPLs were mostly extracted in the Folch aqueous phase and submitted to LC-MSn following the steps
described in the Material and Methods section. Each peak corresponds to a different fragment of the same GIPL
species (parent ion). The annotated spectrum corresponds to a GIPL with the following structure: Hex6-(AEP)HexNInsP-C16:0/C18:1-AAG (parent ion mass of 2060 a.m.u). The GIPL structure is represented on the top right corner
of the figure. AAG, Alkylacylglycerol; AEP, aminoethylphosphonate; Hex, hexose; HexN, hexosamine; InsP, myoinositolphosphate.
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Figure 17: Representative annotated tandem MS spectrum of a T. cruzi trypomastigote GIPL.
T. cruzi TCT GPI-APs were extracted with 9% n-butanol and digested with proteinase K. Purified GPIs were then
submitted to LC-MSn following the steps described in the Material and Methods section. Each peak corresponds to a
different fragment of the same GIPL species (parent ion). The annotated spectrum corresponds to a GIPL with the
following structure: Hex6-(AEP)HexN-InsP-C16:0/C18:1-AAG (parent ion mass of 2025.39 a.m.u.). The GIPL
structure

is

represented

on

the

top

right

corner

of

the

figure.

AAG,

Alkylacylglycerol;

aminoethylphosphonate; EtNP, Ethanolaminephosphate,; Hex, hexose; HexN, hexosamine;
inositolphosphate.
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AEP,

InsP, myo-

3.3.2 Trends in the structures of T. cruzi GIPLs and GPIs
Using this methodology, we were able to identify over 140 GIPL and GPI species from
the three parasite life-cycle stages (i.e., Epi, ICA, and TCT) investigated in this study. Out of
these, 44 had not been described to date. Interestingly, Epis had the largest GIPL and GPI
diversity, but had the least number of species shared with any other life-cycle stages. Conversely,
the mammal-dwelling (ICA and TCT) stages shared over 50% of their species in both GPI and
GIPL fractions. GPI fractions were noticeably less diverse in TCTs and ICAs (tGPI and iaGPI,
respectively) than in their GIPL counterparts (tGIPL and iaGIPLs, respectively), but were very
diverse in Epis (Fig. 18).

Figure 18: Distribution of the number of identified GIPLs and GPI-APs in the different T. cruzi life stages.
T. cruzi GIPLs obtained in the Folch aqueous phase and GPI-APs from the 9% n-butanol extraction submitted to
LC-ESI-MS2 following the steps described in the Materials and Methods section. The resulting MS2 spectra were
analyzed and annotated manually. All structures characterized in this work were grouped according to their
distribution across the different parasite forms.
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In order to better understand these trends, we performed the relative quantification of the
different lipid and glycan moieties present in GIPLs and GPIs from each life-cycle stage of T.
cruzi. To this end, the first analysis that we conducted was the determination of the relative
abundance of lipid moieties composed of either Cer or AAG in GIPLs and GPIs derived from the
three life-cycle stages of this parasite. We observed that GIPLs and GPIs from the mammaldwelling (ICA and TCT) stages contain much higher levels of AAG lipid moieties than in Epis.
In all cases, however, AAGs were more abundant in GPIs than in GIPLs, which is in agreement
to other reports in the literature (79,138,193). As previously described (138,140,194,211,212),
most eGIPL species identified here contain a Cer moiety. However, we also report appreciable
levels of Cer-containing GPIs in this life-stage, which had not been observed in other studies
(Fig. 19). We attribute this to the fact that we have used an instrument with much higher
resolution than the instruments used in previous studies, which allowed us to identify the lipid
moieties of these molecules with higher confidence. Also, the greater sensitivity of this
instrument allowed for the identification of several low-abundance species which had not been
previously described.
Next, we compared the most abundant lipid moieties of each of the three life-cycle stages
aforementioned. Large structural differences were observed when the lipid moieties of the
mammal-dwelling stages were compared to the moieties found in both eGIPLs and eGPIs. In
general, tGIPLs and tGPIs were enriched in C16:0/C16:0-, C16:0/C18:1-, and C16:0/C18:2AAGs. The levels of the latter two moieties were significantly larger in tGPIs than in tGIPLs. A
similar trend was observed for iaGPIs and iaGIPLs, although their levels were not as expressive
as the levels found in TCTs. Conversely, eGIPLs contained very low levels of AAG, with most
of the species containing saturated fatty acids (primarily C16:0, C18:0, and C24:0). eGPIs had

77

significantly larger levels of AAG than eGIPLs, but also contained mostly saturated fatty acids.
Conversely, eGIPLs contained predominantly a Cer moiety with d18:0 (sphinganine) sphingoid
base and saturated fatty acid (mostly C16:0, C24:0, or C26:0), whereas eGPIs contained Cer with
either d18:0- or d18:1- sphingoid base,mostly with a saturated fatty acid. Curiously, TCTs had
no significant levels of Cer, but iaGIPLs contained a large amount of d18:0- and d18:1-sphingoid
bases. iaGPIs also contained Cer, including high levels of C24:0/d18:1-Cer, which was
significantly more abundant in this stage than in TCTs and ICAs. As a whole, the GIPLs and
GPIs from the mammal-dwelling stages of this parasite tend to have significantly more lipid
moieties containing unsaturated fatty acids than in Epis, which tend to have lipid moieties with
predominantly saturated fatty acids (Fig. 20).
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Figure 19: Ceramide and alkylacylglycerol lipid moiety distribution in different life-cycle stages of T. cruzi.
GIPLs extracted in the Folch aqueous phase and GPI-APs obtained with 9% n-butanol were submitted to LC-ESIMS2 following the steps described in the Materials and Methods section. The relative quantification of different lipid
moieties was performed by comparing the area of the peak corresponding to each GIPL or GPI species to the sum of
all areas corresponding to every species identified in each nano-LC-MS run. Results are expressed as relative
percentage of the total.
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Figure 20: Distribution of the most abundant GIPL and GPI lipid moieties in different T. cruzi life-cycle
stages. GIPLs obtained in the Folch aqueous phase and GPI-APs extracted with 9% n-butanol were submitted to
LC-ESI-MS2 following the steps described in the Materials and Methods section. The relative quantification of
different lipid moieties was performed by comparing the area of the peak corresponding to each GIPL or GPI
species to the sum of all areas corresponding to every species identified in each nano-LC-MS run. Results are
expressed as relative percentage of the total. ***, p<0.001, using ANOVA statistical analysis
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The analysis of the GIPL and GPI glycan moieties also showed significant differences
between Epis and the mammal-dwelling ICA amd TCT stages of T. cruzi. As a whole, eGIPLs
and eGPIs displayed almost no glycan diversity, with the vast majority of the species containing
a glycan core of (EtNP)Hex5(AEP)HexN-InsP (fragment at m/z 1462.39). tGIPLs and iaGIPLs
have very similar glycan moiety distributions, and an overall larger diversity than eGIPLs. Also,
the mammal-dwelling stages tend to have, on average, slightly larger glycan moieties than
eGIPLs. As mentioned above, the vast majority of iaGIPLs and tGIPLs have no extra EtNP or
AEP residue, which is present in most of the glycan moieties found in eGIPLs. In all cases, most
GPIs derived from all life-cycle stages have a glycan core comprising (EtNP)Hex5(AEP)HexNInsP

.

However,

the

mammal-dwelling

stages

also

have

a

high

proportion

of

(EtNP)Hex4(AEP)HexN-InsP) glycan core, which is significantly less abundant in eGPIs (Fig.
21). Curiously, we have also identified a few GIPLs containing 1-2 pentose residues, which had
not been previously described. Monosaccharide compositional analysis by GC-MS revealed the
presence of xylose (Xyl), but no other pentose, on GIPL and GPI fractions of the two mammaldwelling stages of this parasite (Fig. 22).
These analyses allowed us to identify several GIPL and GPI structural features not shared
between T. cruzi and their mammalian hosts (including humans) (summarized on Table 4). Of
interest, we observed that AEP substituents bound to HexN (AEP-HexN) was present in nearly
all GPI and GIPL species from the three life-cycle stages of this parasite. Other interesting
features include the presence of Xyl on a few GIPL species, the high abundance of AAGs
containing unsaturated fatty acid (C18:1 or C18:2), and the presence of α-Gal residues in GPIs
and GIPLs derived from TCTs and ICAs.
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Figure 21: Distribution of the most abundant GIPL and GPI glycan moieties in different T. cruzi life-cycle
stages.
Aqueous Folch phase GIPLs and 9% n-butanol GPI-APs were extracted, processed, and submitted to LC-ESI-MS2
following the steps described in the Materials and Methods section. The relative quantification of different glycan
moieties was performed by comparing the area of the peak corresponding to each GIPL or GPI species to the sum of
all areas corresponding to every species identified in each nano-LC-MS run. Results are expressed as relative
percentage of the total. ***, p<0.001, using ANOVA statistical analysis.
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Figure 22: GPI and GIPL monosaccharide compositional analysis. GIPLs from the Folch aqueous phase and
GPI-APs extracted with 9% n-butanol were processed according to the steps described in the Material and Methods
section. The derivatized samples were analyzed by GC-MS, and peaks were identified according to their retention
times and fragmentation pattern, as compared to an internal standard mix.
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Table 4: Major structural differences between mammalian and T. cruzi GPIs.

T. cruzi GIPL structures were characterized using the GPIomic approach. Information about the structural features
from mammalian GPIs was collected from available literature (65,139,142,143,177). The structural features unique
to each group are indicated. AAG, alkylacylglycerol; Cer, ceramide; DAG, diacylglycerol; EtNP,
ethanolaminephosphate; AEP, aminoethylphosphonate; Man, Mannose; α-Gal, α-Galactose; β-GalNAc, β-Nacetylgalactosamine.

Given the differences described above, we proceeded to compare the protein profile of
the GPI-AP enriched fractions (9% n-butanol) from the three life-cycle stages of T. cruzi using a
proteomics pipeline. To this end, we focused only on the proteins that had a high probability of
being GPI-anchored according to the FragAnchor algorithm (University of Hawaii at Manoa)
http://navet.ics.hawaii.edu/~fraganchor/NNHMM/NNHMM.html. In total, we identified 54 GPI84

APs, the majority of which were unique to the TCT stage. As was the trend for the GPIs and
GIPLs, the mammal-dwelling stages shared the most number of proteins, and Epis shared the
least number of proteins with any other life-stage. In fact, Epis had a very low abundance of
GPI-APs (n=13) when compared to the other two stages (n= 49) (Fig. 23).

Figure 23: Distribution of the number of identified GPI-APs in the different life-cycle stages of T. cruzi.
T. cruzi GPI-APs were extracted with 9%n-butanol, digested with trypsin, and submitted to LC-ESI-MS/MS
following the steps described in the Materials and Methods section. The resulting MS2 spectra were analyzed using
the Proteome DiscovererTM software (Thermo Scientific), followed by a second analysis using the ScaffoldTM
software (Proteome Software, Inc). Bona fide GPI-APs were identified using the FragAnchor software (University
of Hawaii at Manoa, Information and Computer Sciences).
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A more detailed analysis of these results showed that the majority of GPI-APs identified
in TCTs belonged to the trans-sialidase (TS) multigene family. Other abundant GPI-APs in this
stage included TolT3 and GP63. These results are in agreement with those by Nakayasu et al.
(213). In spite of not having the same GPI-AP diversity as TCTs, ICAs had higher levels of
MASPs and two uncharacterized proteins unique to this stage. These results are summarized on
Table 5.

Table 5: T. cruzi GPI-APs identified by proteomic analysis of the 9% n-butanol fraction from
Epi, ICA, and TCT stages.

Total number of spectra countsb
Accession
Numbera

Identified Protein

Epi

ICA

TCT

Trans-sialidase (TS) family
Trans-sialidase, putative

Q4CSI1_TRYCC

0

0

236

Trans-sialidase, putative

Q4DVJ1_TRYCC

0

0

184

Trans-sialidase, putative

Q4CRR3_TRYCC

0

1

91

Trans-sialidase, putative

Q4CXS5_TRYCC

0

0

71

Trans-sialidase, putative

Q4CUU4_TRYCC

0

0

57

Trans-sialidase, putative

Q4CUS9_TRYCC

1

0

54

Trans-sialidase, putative

Q4D9H3_TRYCC

0

0

41

Trans-sialidase, putative

Q4CXW0_TRYCC

0

0

39

Trans-sialidase, putative

Q4CPW8_TRYCC

0

0

38

Trans-sialidase, putative

Q4CN26_TRYCC

0

0

35

Trans-sialidase, putative

Q4CTA6_TRYCC

0

0

35

Trans-sialidase, putative

Q4CSS2_TRYCC

0

9

33

Trans-sialidase, putative

Q4DLR5_TRYCC

0

0

30
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Trans-sialidase, putative

Q4DQA2_TRYCC

0

1

29

Trans-sialidase, putative

Q4E1H2_TRYCC

0

0

28

Trans-sialidase, putative

Q4DCG7_TRYCC

0

1

27

Trans-sialidase, putative

Q4D2F9_TRYCC

0

0

22

Trans-sialidase, putative

Q4CRY2_TRYCC

0

1

13

Trans-sialidase, putative

Q4CQV3_TRYCC

0

0

9

Trans-sialidase, putative

Q4DVE4_TRYCC

1

3

0

Surface protein TolT, putative

Q4CNL2_TRYCC

0

10

81

Surface protein TolT, putative

Q4CM39_TRYCC

0

10

72

Surface protein TolT, putative

Q4CM38_TRYCC

0

0

51

TolT3

O96649_TRYCR

0

12

48

Surface protease GP63, putative

Q4DVY4_TRYCC

0

0

34

Surface protease GP63, putative

Q4CQ32_TRYCC

0

0

12

Surface protease GP63, putative

Q4E479_TRYCC

0

0

5

Mucin-associated surface protein (MASP), putative

Q4CS13_TRYCC

0

6

6

Mucin-associated surface protein (MASP), putative

Q4DYV1_TRYCC

0

1

4

Mucin-associated surface protein (MASP), putative

Q4DM97_TRYCC

0

7

0

Mucin-associated surface protein (MASP), putative

Q4DKW6_TRYCC

0

3

0

Mucin TcMUCII, putative

Q4E483_TRYCC

0

5

2

Mucin TcMUCII, putative

Q4E284_TRYCC

0

4

1

K2NK03_TRYCR

3

4

0

TolT family

GP63 family

MASP family

Mucin family

TASV family
Surface antigen TASV, putative,mucin-like glycoprotein, putative
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K4DKF0_TRYCR

4

3

13

Uncharacterized protein

Q4E1W3_TRYCC

0

0

12

Uncharacterized protein

Q4E1V5_TRYCC

0

0

5

Uncharacterized protein

K2MMA3_TRYCR

0

1

3

Uncharacterized protein

K4DXF9_TRYCR

0

31

0

Uncharacterized protein

Q4DXT4_TRYCC

0

7

0

Uncharacterized protein

K4DKF3_TRYCR

0

5

0

Uncharacterized protein

Q4DIA5_TRYCC

2

3

0

Uncharacterized protein

V5BPJ5_TRYCR

3

0

0

Vesicle-associated membrane protein, putative

Uncharacterized proteins

a

UniProt database

b

The total number of spectral counts gives a semi-quantitative idea about the abundance of the identified protein.
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3.4 Discussion

Here, we have successfully implemented the modified GPIomic approach to characterize
for the first time the GPIome of the mammal-dwelling stages of T. cruzi, including the first
descriptions of ICA- and TCT-derived GPIs. As mentioned above, we have described 140
GPI/GIPL species, many of which are novel to the literature. It is clear from this study that
GIPLs and GPI-APs from TCTs and ICAs share many structural features not found in
appreciable levels in GIPLs/GPIs derived from Epis. These features include the enrichment in
AAG lipid moieties containing unsaturated fatty acid (C18:1 or C18:2). This is especially
noticeable in GPI-AP fractions, as previously described (140,141). eGIPLs and eGPIs, on the
other hand, tend to either have ceramide moieties or AAG moieties with saturated fatty acid
substituents (mostly C16:0 or C18:0)

(79,138,214). The presence of mature GPIs with AAG

moieties containing unsaturated fatty acids is in stark contrast to what has been described in T.
brucei, P. falciparum, Leishmania spp., yeast, T. gondii and in mammals. In most cases, the lipid
moieties of GPIs are either composed of diacylglycerol (DAG) (mammals, T. brucei,
Plasmodium falciparum and T. gondii) or AAG containing a saturated fatty acid substituent, as
observed inT. cruzi epimastigotes, Leishmania ssp. and mammals (143,144,154,176,177). Unlike
TCTs, ICAs also express high levels of Cer-containing GPIs. TheseCer moieties, however,
tended to have much longer fatty acid substituents than in Epis. GPIs containing Cer moieties are
rarely found, having only been described in T. cruzi (79,138,214,215), Saccharomyces cerevisae
(216), and Dictyostelium discoideum (217).
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The large structural differences between the mature GPIs and GIPLs derived from Epis,
ICAs, and TCTs suggest that T. cruzi is able to regulate several of the steps involved in the GPI
and GIPL biosynthetic pathway, so theparasite can adapt to the specific needs of each of its lifecycle stages. To date, very little is known about the GPI and GIPL biosynthetic pathway in T.
cruzi. Recently, a study was conducted to characterize genes encoding for key components of the
GPI/GIPL biosynthetic pathway in this species, based on their sequence similarity to orthologous
genes found in yeast, mammals, T. brucei, and P. falciparum. Using yeast complementation and
cellular localization studies, the authors were able to identify 18 components of this pathway
(218). Interestingly, in spite of the structural differences between the mature GPIs and GIPLs
derived from the three parasite life-stages, all 18 genes described in that study were
constitutively expressed in all life-stages of T. cruzi. This suggests that the structural differences
found in the GIPLs and GPIs from the different stages of this parasite are not generated through
a mechanism dependent on the regulation of the levels of distinct protein components of the GPI
and GIPL biosynthetic pathway. We suggest that these differences might be achieved through
changes in substrate availability and in post-translational modifications affecting the activity of
different components of the GIPL and GPI biosynthetic machinery. These changes in substrate
availability can be partially explained from the fact that Epis and the mammal-dwelling stages of
this parasite inhabit very different environments. It has been shown, for instance, that the
metabolism of ICAs and of their host cells are interconnected (219). On that study, it was shown
that parasite survival is dependent on cofactors and metabolites incorporated from the host cells.
Considering the striking differences in the extracellular environment of the insect-dwelling and
mammalian-dwelling stages of this parasite, is would be reasonable to assume that each stage of
this parasite would have access to very different precursors for GPI and GIPL synthesis. Similar
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results were recently found by Kleohn et al. in Leishmania mexicana (220). These authors
showed that intracellular amastigote stages were able to incorporate 2H2O-labeled pentose
sugars, fatty acids, and amino acids from macrophages in the murine footpad lesion.
Interestingly, lesion-derived parasite showed a considerably lower growth rate, strongly
suggesting a refined adaptive strategy to survive within the host for longer periods without
activating immune defense mechanisms.
As aforementioned, one of the most remarkable differences between the GIPLs and GPIs
derived from the different life-stages of T. cruzi lies on their lipid moieties. In general, it has
been described that GPI precursors in mammals and in yeast tend to have AAG moieties with an
unsaturated fatty acid at the sn-2 position (usually, arachidonic acid, C20:4), which is substituted
by a saturated fatty acid (usually, C18:0) during the lipid remodeling stage that takes place after
the covalent attachment of the GPI to the mature protein C-terminus. This also happens to yeast,
despite the fact that several GPIs suffer a more drastic AAG to Cer substitution (185,221,222). T.
brucei GPIs are also remodeled, with the mature structure having mostly a dimyristoyl(C14:0/C14:0) DAG moiety (143). Recent studies show that this fatty acid remodeling takes
place during trafficking of GPI-APs from the Golgi network to the plasma membrane, and that a
disruption in this remodeling leads to intracellular GPI-AP accumulation (143,144,185,222).
Many authors suggest that the presence of the straight saturated lipid chains of these mature GPIs
is required for their lipid-raft association, which is hypothesized to be an important determinant
of their biological function (144,223). This theory would agree well with the data we have
described for T. cruzi Epis (138), and with what has been described for metacyclic
trypomastigotes (79), but not with what we describe in ICAs and TCTs. The prevalence of AAG
moieties containing unsaturated fatty acids would suggest that either T. cruzi makes use of a
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different sorting mechanism, or that the association of GPI-APs to lipid rafts is not a dominant
feature of these parasites. We have in the past, however, shown that the presence of these
unsaturated fatty acids is relevant for the production of proinflammatory cytokines by host
immune cells, through the activation of Toll-like receptor 2 (TLR2) (140,141,160). It is possible
that the relevance of unsaturated fatty acid substituents during infection outweighs any potential
benefits involved in the association of T. cruzi-derived GPI-APs to lipid rafts, or that having
GIPLs and GPI-APs uniformely distributed across the membrane is in itself beneficial to these
parasites.
The enzymatic machinery involved in the GPI lipid remodeling pathway has not yet been
fully described in any organism. It is, however, known that the first steps in the lipid remodeling
pathway in mammalian CHO cells requires a PLA2 activity to remove the unsaturated fatty acid
from the GPI precursor, and of an acyltransferase activity to generate a mature GPI containing a
saturated fatty acid at the sn-2 position of its glycerol backbone. In these organisms it is known
that either the post-GPI attachment to proteins 2 (PGAP2) by itself or a complex containing this
protein is involved in both of these steps (224). The same observation has also been made for the
yeast PGAP2 homolog, GUp1p, which is important for both AAG remodeling and for the
enzymatic steps that will lead to ceramide remodel (225). Both of these proteins belong to the
membrane-bound-O-acyltransferase (MBOAT) family, which are speculated to have an affinity
for saturated fatty acids (223,225,226). Although only a few studies have been conducted to
describe the structure of GPI precursors in T. cruzi, it is known from classic experiments that
these precursors have AAG moieties that closely resemble the AAG moieties from T. brucei GPI
precursors (227). In this case, the lipid remodeling in Epis could take place through similar steps
as those described for T. brucei, yeast, and in mammals. It is possible that T. cruzi has a PGAP2
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ortholog, which would be involved in the deacylation of the fatty acid at the sn-2 position of the
AAG moiety of the GPI precursors from Epis, and of reacylating it with a saturated fatty acid
(C16:0 or C18:0). We have so far formulated two hypotheses that would explain the presence of
unsaturated fatty acids in mature GPIs/GIPLs from the mammal-dwelling stages of T. cruzi. The
first hypothesis is that the putative T. cruzi PGAP2 homolog, or another protein in the complex,
is either not expressed or inactive in TCTs and ICAs. In this case, the deacylation step of the
remodeling pathway would not take place, and the mature GPIs/GIPLs would retain their
unsaturated fatty acid moiety. The other alternative is that the GPI/GIPL precursors in the
mammal-dwelling stages of this parasite retain the myo-inositol-ring acylation for a longer time
than in Epis. The presence of this modification would hinder the PLA2 from the remodeling
machinery, also leading to the expression of mature GPI/GIPLs retaining the unsaturated fatty
acid at the sn-2 position of the AAG moiety. This would be in agreement with observations that
some mature GPI-APs (i.e., Tc-85 surface glycoproteins) in T. cruzi trypomastigotes retain a
fatty acid substitution at the C-2 position of their myo-inositol (228). Both hypotheses have the
benefit of being parsimonious, since we are proposing that the differences between the structure
of GPIs/GIPLs from Epis and the mammalian-dwelling stages of T. cruzi can be explained by the
absence of one enzymatic activity. This would make it more difficult, however, for the
GPI/GIPL lipid remodeling in the mammal-dwelling stages of T. cruzi to be explored for the
development of new therapies for Cd.
The presence of Cer moieties on GIPLs and GPIs from T. cruzi have also been proposed
as potential targets for the development of novel drugs for Cd. This idea comes from studies that
show that GPIs derived from Metas are enriched in Cer moieties, and that the incorporation of
said moieties to nascent GPIs require the de novo synthesis of sphingoid bases (79,229,230).
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Also, it has been shown that several steps in the biosynthesis of sphingolipids in T. cruzi are not
shared with mammals (230). Although we agree that this might be a sound strategy to prevent
vector-borne transmission of T. cruzi to humans, we do not believe that this would be a good
approach to the treatment of chronic Cd. The reasons for this are that our results show that
neither TCTs nor ICAs have high levels of Cer-containing GIPLs and GPIs, and that there is no
evidence that these two life-cycle stages would rely as heavily on the de novo Cer synthesis as is
the case for the insect-dwelling stages. We suggest that a better target for the development of
novel therapies for Cd should at the same time be relevant for parasite infectivity and survival in
the human host, be conserved and ubiquitous in the mammal-dwelling stages of the parasite, and
not be shared with the mammalian host.
The GPIome of the mammal-dwelling stages of this parasite confirmed the observations
made in Epis, where over 99% of GIPL and GPI species in T. cruzi contain an AEP substitution
bound to the GlcN residue of their conserved glycan core (138,192-194). The fact that this
modification is highly conserved suggests that it might play an important function in either
parasite survival and/or during infection. As mentioned above, we also hypothesize that this
modification could play an analogous role as that of the addition of EtNP to the second mannose
residue of nascent GPI-APs in mammalian cells (144), where it is believed to serve as part of a
quality control mechanism. We believe that further research in conserved structural features of
lipids and glycolipids not shared between T. cruzi and humans could lead to the development of
new therapies for Cd. Here, we suggest that one of these potential targets would be the AEP
biosynthetic pathway (not present in mammals) responsible for the generation of the AEP
residue that is covalently attached to the GlcN residue of great majority of T. cruzi GIPLs and
GPIs
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APPENDIX
SUPPLEMENTARY FIGURES
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Figure S1. Fractionation of phospholipid standards using POROS R1 perfusion chromatography. A
mixture of phospholipid standards, containing synthetic C16:0-lyso-PAF (LPAF) (m/z 488.4), C16:0-lyso-LPC
(LPC) (m/z 502.4), C16:0-PAF (PAF) (m/z 530.5), and purified diacyl-PCs (700–900 m/z range), was suspended in
HPLC-grade water and applied onto the POROS R1 mini-column, which was eluted with a 0%–50% n-propanol
gradient. All fractions were diluted in methanol containing 5 mM LiOH and analyzed by direct infusion in an
LTQXL ESI-LIT-MS, in positive-ion mode.
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Figure S2. ESI-LIT-MSn analysis of major T. cruzi ion species enriched by POROS R1 fractionation. (A) ESILIT-MS2 spectra. Phospholipid standards (C16:0-PAF, C18:0-LPC, and C18:1-LPC) or purified T. cruzi
phospholipids from the POROS R1 25% n-propanol fractions were diluted in methanol containing 5 mM LiOH and
then infused directly into the LTQXL MS using an Advion Triversa NanoMate nanoelectrospray system. Major
parent-ion species observed in the MS spectra (Fig. 2) were subjected to MS2 fragmentation. (B) ESI-LIT-MS3
spectra of selected ion species found in (A). Ion species corresponding to a neutral loss of 59 m/z (trimethylamine)
from the parent ion were selected for MS3 fragmentation.
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Figure S3. Determination of the acyl
chain and double bond positions on T.
cruzi C18:1-LPC. (A–B) Acyl chain
position analysis. The sn-1 C18:1-LPC
and

sn-2

C18:1-LPC

regioisomer

standards were generated by treatment of
18:1(Δ9-cis)-diacyl-PC with PLA2 and
PLA1, respectively, as described in
Materials and Methods. (A) MS2 analysis.
All LPCs were diluted in methanol
containing 2.5 mM NaCl and analyzed by
direct infusion using an Advion Triversa
NanoMate

nanoelectrospray

system

coupled to an LTQXL MS. MS2 spectra
were acquired in positive-ion mode. (B)
MS3 analysis. All LPCs were diluted in methanol containing 2.5 mM LiOH and analyzed by MS3 (MS2 528.7→MS3
469.3), under the same MS experimental conditions. (C) Double-bond position analysis. The sn-1 C18:1(Δ6-cis)LPC and sn-1 C18:1(Δ9-cis)-LPC standards were generated by treatment of 18:1(Δ6-cis)-diacyl-PC and 18:1(Δ9Cis)-diacyl-PC with PLA2, respectively, as described in Materials and Methods. The position of the unsaturation on
the acyl moiety of T. cruzi C18:1-LPC was determined by comparing the MS4 fragmentation pattern of this ion (MS2
528.7→MS3 469.3→MS4 339.3) to the fragmentation pattern of sn-1 C18:1(Δ6-cis)-LPC and sn-1 C18:1(Δ9-cis)LPC under identical conditions to (B). Diagnostic ions (bold) are indicated.
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Figure S4. Tandem ESI-LIT-MS spectra of the low-abundance T. cruzi LPC-species enriched by POROS R1
fractionation. T. cruzi phospholipids from the 25% n-propanol fractions were diluted in methanol containing 5 mM
LiOH and then infused directly into an LTQXL ESI-LIT-MS. Selected peaks were sequentially fragmented (MS2MS4) by CID, as follows: C16:0-LPC (MS2 502→MS3 443→MS4 313); C16:1-LPC (MS2 500→MS3 441→MS4
311); C22:4-LPC (MS2 578→MS3 519→MS4 389); and C22:6-LPC (MS2 574→MS3 515→MS4 385).
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Figure S5. Quantification of LPC species in extracellular vesicles (EV) and EV-free supernatant of T. cruzi.
C10:0-LPC (m/z 418) was used as an internal standard for quantification of the most abundant T. cruzi LPC species.
C10:0-LPC was added to fresh pellets or EV preparations from Epis and Metas, prior to lipid extraction with C:M
(2:1, v/v) and C:M:W (1:2:0.8, v/v/v), followed by Folch's partition. The Folch lower phase was analyzed by ESILIT-MS. C18:1- and C18:2-LPC are indicated at m/z 528 and 526, respectively. ePellet, Epi total pellet; eV2, Epiderived ectosomes; eV16, Epi-derived exosomes; eVF, Epi-derived EV-free supernatant (or conditioned medium);
mPellet, Meta total pellet; mV2, Meta-derived ectosomes; mV16, Meta-derived exosomes; mVF, Meta-derived EVfree supernatant.
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Figure S6 Structural representation of the PAFR model. (A) Arrangement of the 7 transmembrane (TM)
helices forming a cavity. (B) The extracellular loops (EL1-EL3). (C) The intracellular loops (CL1-CL3). Each TM
(alpha-helix) is indicated in a different color. TM1, blue; TM2, red; TM3, dark gray; TM4, orange; TM5, yellow;
TM6, purple; TM7, green.
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Figure S7. Main Ramachandran plot of the PAFR model. The main Ramachandran plot represents all amino acid
residues by squares, whereas the glycine (Gly) residues are separately identified by black triangles, because these
are not restricted to the regions in the generic Ramachandran plot. Red (A, B, and L) and dark yellow (a, b, l, and p)
colors correspond to combinations of phi (Φ) and psi (Ψ) torsion angles of amino acid residues in the most favorable
and additional allowed regions, respectively. In addition, pale yellow (~a, ~b, ~l, and ~p) and white colors represent
less favorable and disallowed regions, respectively. The amino acid residues lying in those regions are highlighted in
red.
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Figure S8. Ramachandran plot for Gly residues of the PAFR model. The second Ramachandran plot considers
only Φ and ψ angles for Gly residues, where the number in parenthesis indicates the total number of these residues
in the primary sequence of PAFR. The favorable combinations of these angles are represented by green areas and
the values of standard deviations greater than 2.5 Å are labeled in red in the graph, describing combinations of
disallowed angles. All Gly residues are in allowed regions, with favorable combinations of angles Φ and Ψ.

130

Figure S9. Analysis of the main-chain
parameters of the PAFR model. The six
graphs on the main chain parameters plot
show how the PAFR model (represented
by the black square) compares with a
database

of

well-refined

protein

structures. The blue band in each graph
represents the results from the wellrefined protein structures; the central line
is the least squares fitting to the mean
trend as a function of resolution, whereas the width of the band on either side of it corresponds to a variation of one
standard deviation from the mean. The six properties plotted are: (a) Ramachandran plot quality assessment; (b)
peptide bond planarity; (c) number of bad contacts per 100 residues; (d) α-carbon tetrahedral distortion (this
property is measured by calculating the standard deviation of the zeta torsion angle); (e) main chain hydrogen bond
energy; and (f) overall G-factor (the overall value is obtained from an average of all the different G-factors for each
residue in the protein structure). The G-factor provides a measure of how “normal”, or alternatively how “unusual”,
a given stereochemical property is and, in PROCHECK, it is computed for the following properties: Φ-Ψ
combination, chi1-chi2 (X1-X2; side chain torsion angles) combination, X1 torsion for those residues that do not have
a X2, combined X3 and X4 torsion angles, omega torsion angles, main chain bond lengths, and main chain bond
angles.
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Figure S10. Analysis of the side-chain parameters of the PAFR model. In a similar way to the main-chain
analysis, the side-chain analysis shows how the PAFR model (black square) compares with well-refined protein
structures. This analysis evaluates five properties: (a) standard deviation values of the Chi-1 gauche minus torsion
angles; (b) standard deviation values of the Chi-1 trans; (c) standard deviation values of the Chi-1 gauche plus; (d)
pooled standard deviation of Chi-1 torsion angles; and (e) standard deviation values of the Chi-2 trans torsion
angles.
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Figure S11. Analysis of geometrical distortions of the PAFR model. The parameters analyzed were: lengths and
bond angles, including atoms of the main and side chains. This analysis shows the amino acid residues with
distorted geometry, including their ideal values (in blue), those found in the model (in red), and the difference
between these values (in green).
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Figure S12. ERRAT analysis of the PAFR model. Errors in non-bonded atom-atom interactions of the PAFR
model were verified by this analysis. The error values were plotted as a function of the position of a sliding residue
in the window. An overall quality factor value of 87% was observed, thus validating the PAFR model.
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Figure S13. ProQM analysis of the PAFR model. A score was given to each residue of the protein model, which
lead to a global quality factor of 0.717, which corroborates the other modelling analyses.
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Figure S14. Comparison of binding modes of PAF and each LPC species to PAFR. (A) C16:0-PAF (cyan) and
C16:0-LPC (yellow); (B) C16:0-PAF (cyan) and C18:0-LPC (orange); (C) C16:0-PAF (cyan) and C18:1-LPC
(green); (D) C16:0-PAF (cyan), and C18:2-LPC (gray). Transmembrane (TM) regions are represented as white rods.
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Figure S15. Unfavorable steric interactions of PAF and LPCs with PAFR. Heteroatoms are represented by
different colors in structures: nitrogen atoms are shown in blue, oxygen in red, and carbon atoms of amino acids in
gray. In ligands, carbon chains are represented by different colors: (A) C16:0-PAF, cyan; (B) C16:0-LPC, yellow;
(C) C18:0-LPC, orange; (D) C18:1-LPC, green; and (E) C18:2-LPC, pink.

137

Table S1. Quantification of LPC species in extracellular vesicles (EVs) and EV-free supernatant
of epimastigotes and metacyclic trypomastigote forms.

LPC species
C18:2-LPC (m/z 526.4)
ePellet d
eV2
eV16
eVF
mPellet
mV2
mV16
mVF
C18:1-LPC (m/z 528.4)
ePellet
eV2
eV16
eVF
mPellet
mV2
mV16
mVF

a

Picomoles of LPC per
106 cells

LPC amount
a, b
(mol ) per parasite

Number of LPC
c
molecules per parasite

2.7
n/a e
0.9
0.7
0.6
0.8

0.36

2.16 x 106

n/a
0.12
0.09
0.08
0.11

n/a
0.72 x 106
0.54 x 106
0.48 x 106
0.66 x 106

n/a
0.24

n/a
1.44 x 106

-17

n/a
1.8
1.3
n/a
1.0
0.7

0.18

1.08 x 106

n/a
0.14
0.09

n/a
0.81 x 106
0.52 x 106

0.3
0.5

0.05
0.07

0.30 x 106
0.43 x 106

n/a
1.9

n/a
0.25

n/a
1.5 x 106

The molar relative response factors (MRRF) of C10:0-LPC and LPC standards were used to calculate the amount
of each LPC molecular species in Folch lower-phase fractions of T. cruzi .

b

The number of parasites was determined before lipid extraction by counting live parasites in a hemocytometer.
Values are means of three determinations. The standard deviation in all cases was <15%.

c

Determined by multiplying the number of moles by the Avogadro’s constant. D

d

ePellet, Epi pellet; eV2, Epi-derived ectosomes; eV16, Epi-derived exosomes; eVF, Epi-derived EV-free
supernatant or fraction; mPellet, Meta pellet; mV2, Meta-derived ectosomes; mV16, Meta-derived exosomes;
mVF, Meta-derived EV-free supernatant or fraction.

e

Not analyzed due to absence or trace amounts of the compound.
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